Document:

Exhibit 10.12

 

EXECUTION COPY

 

Certain identified information has been excluded
from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private
or confidential. Double asterisks denote omissions.

 

AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT

 

THIS
AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into as of the
16th day of August, 2016 (the “Effective Date”) by and between Akriveia Therapeutics Inc., a for-profit company
with a registered address at 615 South DuPont Highway, Dover, DE 19901 (“Licensee”) and City of Hope, a
California nonprofit public benefit corporation located at 1500 East Duarte Road, Duarte, California 91010 (“City of
Hope” or “COH”). Licensee and COH are each sometimes referred to herein individually as a
 “Party” and collectively as the “Parties.”

 

WHEREAS:

 

A.            COH
operates an academic research and medical center that encourages the use of its inventions, discoveries and intellectual property for
the benefit of the public and COH owns or Controls (as defined below) certain Patent Rights (as defined below) useful in the Field (as
defined below);

 

B.             Licensee
is a company to be dedicated to the commercial development and exploitation in the Field of products and services that incorporate one
or more of the technologies described in the Patent Rights;

 

C.             On
May 24, 2016 (the “Original Effective Date”), the Parties entered into (i) an Exclusive License Agreement
(the “Original Agreement”), pursuant to which COH granted Licensee an exclusive license under the Patent Rights to
make, have made, use, offer for sale, sell and import Licensed Products (as defined below) and to perform Licensed Services (as defined
below), in the Field, in the Territory (as defined below) and (ii) a side letter agreement, pursuant to which the Parties agreed
to amend and restate the Original Agreement following Licensee’s restructuring transaction; and

 

D.            On
May 25, 2016, Licensee entered into a restructuring transaction pursuant to which it became a wholly-owned subsidiary of Akriveia
Therapeutics, LLC (the “Parent”).

 

NOW,
THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the amount
and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

ARTICLE 1: DEFINITIONS

 

1.1            “Act”
means the Securities Act of 1933, as amended.

 

1.2            “Affiliate”
of a Party means a Person that, directly or indirectly (through one or more intermediaries) controls, is controlled by, or is under common
control with such Party. For purposes of this Section 1.2, “control” means (i) the direct or indirect ownership
of 50 percent or more of the voting stock or other voting interests or interests in profits, or (ii) the ability to otherwise control
or direct the decisions of board of directors or equivalent governing body thereof.

 

     

     

    

 

EXECUTION COPY

 

1.3            “Business
Day” means any day, other than a Saturday, Sunday or day on which commercial banks located in Los Angeles, California, are
authorized or required by law or regulation to close.

 

1.4            “Change
of Control” means (i) any transaction or series of related transactions following which the holders of Parent’s
or Licensee’s capital stock or membership or equity interests immediately prior to such transaction or series of related transactions
collectively hold less than 50% of such outstanding equity interests of Parent or Licensee, as applicable, entitled to (a) vote with
respect to the election of directors (or positions having a similar function) or (b) receive the proceeds upon any sale, liquidation
or dissolution of Licensee or Parent, as applicable (but in each case other than in connection with a bona fide Equity Financing of Licensee
or Parent, as applicable); (ii) a sale, transfer or other disposition to a Third Party, in a single transaction or series of related
transactions, of all or a material portion of Licensee’s or Parent’s interest in the Licensed Product; (iii) a sale,
transfer or other disposition to a Third Party, in a single transaction or series of related transactions, of all or a material portion
of Licensee’s or Parent’s, as applicable, right, title, or interest in its assets taken as a whole (but in each case of the
foregoing (ii) and (iii) other than by grant of sublicense(s) or in connection with reorganization of Licensee); (iv) an
initial public offering of the stock of Licensee or Parent; (v) the merger of Licensee or Parent, as applicable with a Third Party
by operation of law or otherwise; or (vi) any assignment of this Agreement by Licensee to a Third Party.

 

1.5            “Commercially
Reasonable Efforts” means the exercise of such efforts and commitment of such resources by Licensee, directly or through
one or more Sublicensees, in a diligent manner consistent with organizations of comparable size and resources in the pharmaceutical industry
for a comparable development or commercialization program at a similar stage of development or commercialization. [**].

 

1.6            “COH
Confidential Information” means Confidential Information disclosed or provided by, or on behalf of, COH to Licensee or its
designees.

 

1.7            “COH
Shares” means the shares of Common Stock of Licensee issued to COH in accordance with Section 4.4.

 

1.8            “Common
Stock” means Common Stock, par value $0.00001 per share, of Licensee.

 

1.9            “Confidential
Information” means: (i) all information and materials (of whatever kind and in whatever form or medium) disclosed by
or on behalf of a Party to the other Party (or its designee) in connection with this Agreement, whether prior to or during the term of
this Agreement and whether provided orally, electronically, visually, or in writing; provided that all such information and materials
initially disclosed in writing or electronically shall be clearly marked as “CONFIDENTIAL” and all such materials and information
initially disclosed orally shall be reduced to writing and marked as “CONFIDENTIAL” within [**] following the date of initial
oral disclosure; (ii) all copies of the information and materials described in (i) above; and (iii) the existence and each
of the terms and conditions of this Agreement; provided further that Confidential Information shall not include information and materials
to the extent a Party can demonstrate through its contemporaneous written records that such information and materials are or have been:

 

    2

     

    

 

EXECUTION COPY

 

(a)            known
to the receiving Party, or in the public domain, at the time of its receipt by a Party, or which thereafter becomes part of the public
domain other than by virtue of a breach of this Agreement or the obligations of confidentiality under this Agreement;

 

(b)            received
without an obligation of confidentiality from a Third Party having the right to disclose without restrictions such information;

 

(c)            independently
developed by the receiving Party without use of or reference to Confidential Information disclosed by the other Party; or

 

(d)            released
from the restrictions set forth in this Agreement by the express prior written consent of the disclosing Party.

 

1.10          “Control(s)”
or “Controlled” means the possession by a Party, as of the Effective Date, of rights sufficient to effect the
grant of rights set forth in this Agreement without violating the terms of any agreement with any Third Party.

 

1.11          “Covers”
or “Covered by,” with reference to a particular Licensed Product or Licensed Service that the manufacture, use,
sale, offering for sale, or importation of such Licensed Product or performance of such Licensed Service would, but for ownership of,
or a license granted under this Agreement to, the relevant Patent Right, infringe a Valid Claim in the country in which the activity occurs.

 

1.12          “Designated
Affiliate” shall mean any wholly-owned subsidiary of Parent or any Affiliate of Licensee that is designated as a “Designated
Affiliate” by Licensee in a notice to COH and which, in connection with such designation, enters into a Designated Affiliate Agreement
with COH.

 

1.13          “Designated
Affiliate Agreement” shall mean an exclusive license agreement granting a Designated Affiliate a license within a part of
the Field, in the form attached hereto as Exhibit C, to be entered into by COH and each Designated Affiliate in accordance
with Section 3.5 hereof.

 

1.14          “Dispute”
means any controversy, claim or legal proceeding arising out of or relating to this Agreement, or the interpretation, breach, termination,
or invalidity thereof.

 

1.15          “Equity
Financing” means the issuance of capital stock of Licensee or Parent, as applicable, in one or more transactions, including
any such capital stock issuable (assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability) upon
the exercise, conversion or exchange of all evidences of indebtedness, shares or other securities directly or indirectly convertible into
or exchangeable for capital stock of Licensee or Parent, as applicable, including all rights, options or warrants to subscribe for, purchase
or otherwise acquire capital stock of Licensee or Parent, as applicable.

 

    3

     

    

 

EXECUTION COPY

 

1.16          “Field”
subject to Section 3.5.2, means the prevention, treatment and diagnosis of all human diseases and disorders.

 

1.17          “First
Commercial Sale” means, with respect to a particular Licensed Product or Licensed Service in a given country, the first
arm’s-length commercial sale of such Licensed Product or the first performance of such Licensed Service following Marketing Approval
in such country by or under authority of Licensee or any Sublicensee to a Third Party who is not a Sublicensee.

 

1.18          “GAAP”
means generally accepted accounting principles, consistently applied, as promulgated from time to time by the Financial Accounting Standards
Board.

 

1.19          “IND”
means an Investigational New Drug application accepted by the FDA.

 

1.20          “Lead
Candidate” means a molecule that has been identified by Licensee in its reasonable business and scientific judgment, as
a potential clinical development candidate and has been selected by Licensee for evaluation as a clinical development candidate.

 

1.21          “License
Year” means each calendar year during the term of this Agreement; except that the first License Year shall commence on the
Effective Date and end on December 31 of the calendar year in which the Effective Date occurs.

 

1.22          “Licensed
Product” means a product [**] that: (i) is Covered by a Valid Claim of the Patent Rights, (ii) is manufactured
by a process or used in a method Covered by a Valid Claim of the Patent Rights, or (iii) contains, as an active ingredient, any substance
the manufacture, use, offer for sale or sale of which is Covered by a Valid Claim of the Patent Rights. By way of clarification, “Licensed
Product” shall include a product manufactured in a country in which such manufacture is Covered by a Valid Claim and thereafter
exported to and sold in a country in which no Valid Claim exists.

 

1.23          “Licensed
Service” means any service the performance of which would, but for the license granted herein, infringe a Valid Claim of
the Patent Rights.

 

1.24          “Licensee
Confidential Information” means Confidential Information disclosed or provided by, or on behalf of, Licensee to COH or its
designees.

 

1.25          “Marketing
Approval” means all approvals, licenses, registrations or authorizations of any federal, state or local regulatory agency,
department, bureau or other governmental entity, including, without limitation, pricing and reimbursement approvals, necessary for the
manufacturing, use, storage, import, transport, distribution, marketing and sale of the applicable Licensed Products or performance of
the applicable Licensed Services in a country or regulatory jurisdiction.

 

1.26          “NPA”
means a New Drug Application to be filed with the FDA, or any equivalent application in jurisdictions outside the United States.

 

    4

     

    

 

EXECUTION COPY

 

1.27          “Net
Proceeds” means the net proceeds actually received by Licensee after deduction of all transaction expenses, finder’s
fees, advisory fees, legal fees, sales commissions or similar amounts paid to brokers or dealers and other costs and expenses incurred
by Licensee or its Affiliates in connection therewith. In the event such net proceeds are not paid to Licensee in cash, the value of such
net proceeds will be the fair market value of the assets constituting such net proceeds.

 

1.28          “Net
Sales” means the total gross amount invoiced by Licensee, its Affiliates (excluding Designated Affiliates) and Sublicensees
(regardless of whether and when such invoices are actually paid) on the sale of the applicable Licensed Products and applicable Licensed
Services to Third Parties (including, without limitation, the provision of any product by Licensee, its Affiliates (excluding Designated
Affiliates) or Sublicensees that incorporates a Licensed Product or Licensed Service but for clarity excluding documented sponsored research
and/or development activities, valued at the actual direct cost of such activities on a fully burdened basis (including reasonable margin
for overhead)), less the following items, as determined from the books and records of Licensee, its Affiliates (excluding Designated Affiliates)
or Sublicensees:

 

[**].

 

In the event that a Licensed Product is a Combination
Product (defined below), Net Sales, for the purposes of determining royalty payments on the Combination Product, shall mean the gross
amount invoiced for the Combination Product less the deductions set forth in clauses (a) – (e) above, multiplied by a
proration factor that shall be determined by the formula [A / (A+B)], where A is the average gross sales price in the relevant country
of a Licensed Product during such period (or similar Licensed Product with the same dosage and route of administration) when sold separately
from the other active component(s) in finished form, and B is the average gross sales price in such country of the other active component(s) during
such period (or similar Licensed Product with the same dosage and route of administration) when sold separately from the Licensed Product
in finished form. For purposes of this Agreement, “Combination Product” means any Licensed Product sold in combination
with one or more other active components which are not Licensed Products and where both the Licensed Product and other active components
are each sold separately in the same dosage and route of administration. For clarity, if no such separate sales exist, the proration factor
shall not be applied.

 

Sales of Licensed Products between or among Licensee,
its Affiliates, or its Sublicensees shall be excluded from the computation of Net Sales, except in those instances in which the purchaser
is also the end-user of the Licensed Product sold. Further, transfers of reasonable quantities of Licensed Product by Licensee, any of
its Affiliates or of its Sublicensee to a Third Party that is not a Sublicensee for use in the development of such Licensed Product (and
not for resale) and transfers of industry standard quantities of Licensed Product for promotional purposes shall not be deemed a sale
of such Licensed Product that gives rise to Net Sales for purposes of this Section 1.28.

 

1.29          “Patent
Rights” means (i) all United States and foreign patents, patent applications, continuations and divisional applications
that claim the patentable inventions disclosed in the COH internal invention disclosures set forth in Exhibit A, including [**],
or the Subject Inventions as defined in the Research Agreement (as defined below) set forth in Exhibit B; (ii) continuation-in-part
applications that repeat a substantial portion of any of the foregoing that are Controlled by COH, (iii) any patents or patent applications
that claim the same invention(s) or claim priority, directly or indirectly, to any of the foregoing, that are Controlled by COH,
(iv) letters patent or the equivalent issued on any of the foregoing throughout the world, and (v) amendments, extensions, renewals,
reissues, and re-examinations of any of the foregoing. Notwithstanding the foregoing, excepting all Subject Inventions as defined in the
Research Agreement, “Patent Rights” shall only include any continuation-in-part application to the extent that claims in such
continuation-in-part application are supported in the specification of the parent application, unless otherwise mutually agreed to in
writing by the parties to this Agreement.

 

    5

     

    

 

EXECUTION COPY

 

1.30          “Person”
means any person or entity, including any individual, trustee, corporation, partnership, trust, unincorporated organization, limited liability
company, business association, firm, joint venture or governmental agency or authority.

 

1.31          “Phase
1 Clinical Trial” means, as to a specific Licensed Product or Licensed Service, a study as described in 21 C.F.R. §
312.21(a) or a comparable clinical study in a country other than the United States.

 

1.32          “Phase
2 Clinical Trial” means, as to a specific Licensed Product or Licensed Service, a study in humans designed with the principal
purpose of determining initial efficacy and dosing of such Licensed Product in patients for the indication(s) being studied as described
in 21 C.F.R. § 312.21(b); or a similar clinical study in a country other than the United States.

 

1.33          “Phase
3 Clinical Trial” means, as to a specific Licensed Product or Licensed Service, a lawful study in humans of the efficacy
and safety of such Licensed Product or Licensed Service, which is prospectively designed to demonstrate statistically whether such Licensed
Product is effective and safe for use in a particular indication in a manner sufficient to file an application to obtain Marketing Approval
to market and sell that Licensed Product or Licensed Service in the United States or another country for the indication being investigated
by the study, as described in 21 C.F.R. § 312.21(c); or similar clinical study in a country other than the United States.

 

1.34          “Research
Agreement” has the meaning set forth in Section 4.13 of this Agreement.

 

1.35          “Research
Expenses” means those direct research and development expenses directly applicable to personnel, supplies and materials
and contracted and outside services, in each case, exclusively related to the development and commercialization of Licensed Products and
Licensed Services; provided that to the extent that any specific personnel, supplies or materials or contracted or outside services
are related to both the development and commercialization of Licensed Products and Licensed Services as well as other activities of Licensee
that are not related to the development and commercialization of Licensed Products and Licensed Services, only that portion of the related
expense that can reasonably be allocated solely to the development and commercialization of Licensed Products and Licensed Services, as
substantiated by the contemporaneous business records of Licensee, may be included in Research Expenses. Research Expenses will be permitted
to include an additional [**]%) percent of the foregoing direct research and development expenses as overhead but otherwise do not include
any indirect costs, overhead, utilities, equipment or facility-related expenses, any general and administrative expenses or other similar
costs. All Research Expenses shall be determined, and all calculations shall be made, in accordance with GAAP.

 

    6

     

    

 

EXECUTION COPY

 

1.36          “Sublicensee”
means any Third Party which enters into an agreement with Licensee or an Affiliate (excluding Designated Affiliates) of Licensee involving
the grant to such Third Party of any rights under the license granted to Licensee pursuant to this Agreement to offer for sale and sell
Licensed Products in a given country or territory. For clarity, the recipient of a sublicense from Licensee as part of any agreement with
a contract research organization acting strictly on behalf of Licensee, contract manufacturing organization or other like organization
acting strictly on behalf of Licensee where such sublicense does not include the right to sell Licensed Products shall be deemed not to
be a Sublicensee for purposes of this Agreement. For the avoidance of doubt, Designated Affiliate Agreements shall not constitute “Sublicensees”
for purposes of this Agreement.

 

1.37          “Sublicense
Revenues” means all consideration, in whatever form, due from a Sublicensee in return for the grant of a sublicense of Licensee’s
rights hereunder, excluding consideration in the form of: (i) royalties received by Licensee and calculated wholly as a function
of sales of Licensed Products or Licensed Services, (ii) payments received by Licensee at or around the milestone event for which
milestone payments are already due to COH according to the schedule listed in Section 4.5, (ii) payments or reimbursement for
documented sponsored research and/or development activities, valued at the actual direct cost of such activities on a fully burdened basis
(including reasonable margin for overhead), (iii) payment or reimbursement of reasonable patent expenses actually incurred or paid
by Licensee and not otherwise reimbursed, or payment of patent expenses required to by paid by Licensee hereunder, (iv) payments
for the purchase of equity in Licensee at the fair market value of such equity, and (v) payments recognized as Net Sales under this
Agreement for which a royalty is payable to COH. By way of clarification, the principal amount of any loan or other extension of credit
provided to Licensee or an Affiliate (excluding a Designated Affiliate) of Licensee in connection with the grant of a sublicense by Licensee
that is other than an arm’s-length credit relationship shall be deemed to constitute “Sublicense Revenues.”

 

1.38          “Territory”
means the entire world.

 

1.39          “Third
Party” means a Person that is neither a Party to this Agreement nor an Affiliate of a Party.

 

1.40          “Valid
Claim” means a claim of a pending patent application or an issued and unexpired patent included in the Patent Rights, which
claim has not, in such jurisdiction been finally rejected or been declared invalid or cancelled by the patent office or a court of competent
jurisdiction in a decision that is no longer subject to appeal as a matter of right.

 

ARTICLE 2: DEVELOPMENT AND COMMERCIALIZATION
EFFORTS

 

2.1            Development
and Commercialization Responsibilities. Licensee and its Sublicensees shall have the sole right and responsibility for, and control
over, all development, manufacturing and commercialization activities (including all regulatory activities) with respect to Licensed Products
and Licensed Services in the Field.

 

    7

     

    

 

EXECUTION COPY

 

2.2            Licensee
Diligence. Licensee shall use Commercially Reasonable Efforts to develop and commercialize Licensed Products and Licensed Services
in the Field, directly or through one or more Sublicensees. Without limiting the foregoing, if Licensee, directly or through one or more
Sublicensees, fails to accomplish any one of “Diligence Milestones” set forth in this Section 2.2 by the date
specified (each a “Deadline Date”) corresponding to such Diligence Milestone, COH shall have the right, on notice to
Licensee, to terminate this Agreement or convert the grant of rights hereunder from exclusive to non-exclusive, without any change in
the other terms and conditions of this Agreement. [**]. Conversion of the license to non-exclusive pursuant to this Section 2.2 shall
not constitute a waiver of COH’s right to terminate the license thereafter if Licensee’s obligations under this Section 2.2
continue to be unmet. [**]. Licensee shall provide COH with prompt written notice upon reaching each Diligence Milestone, which notice
shall be accompanied by written documentation substantiating the achievement of any such Diligence Milestone. Upon written request by
COH, Licensee shall supply additional written documentation reasonably requested by COH to confirm the achievement of any such Diligence
Milestone.

 

	“Deadline Date”	“Diligence Milestone”
	 	 
	1. [**] from the Original Effective Date	Licensee or Parent to receive aggregate Net Proceeds of not less than $[**] through any combination of: [**].
	 	 
	2. [**] from the Original Effective Date	Unless Licensee or Parent [**], Licensee or Parent to receive aggregate Net Proceeds of not less than $[**] in total (i.e., including the $[**] in 1 above) through any combination of: [**].
	 	 
	3. [**] from the Original Effective Date	[**].
	 	 
	4. [**] from the Original Effective Date	[**],
	 	 
	 	or
	 	 
	 	[**].
	 	 
	5. [**] from the Original Effective Date	[**],
	 	 
	 	or
	 	 
	 	[**].
	 	 
	6. [**] from the Original Effective Date	[**],
	 	 
	 	or
	 	 
	 	[**].
	 	 
	7. [**] from the Original Effective Date	
    [**],

     

    or

	 	 
	 	[**].

 

    8

     

    

 

EXECUTION COPY

 

For avoidance of doubt, the
efforts and achievements of all Designated Affiliates acting under Designated Affiliate Agreements shall be included in determining whether
Licensee has satisfied its obligations under this Section 2.2.

 

2.3            Governance.
COH and Licensee shall each designate one individual to serve as the main point of contact for communications related to development and
commercialization of Licensed Products and Licensed Services under this Agreement (each a “Designated Representative”).
The initial Designated Representative of COH shall be [**] and the initial Designated Representative of Licensee shall be [**]. Each Party
may replace its Designated Representative at any time upon prior notice to the other Party. Licensee shall keep COH reasonably informed
as to progress in the development and commercialization of Licensed Products and Licensed Services. Without limiting the foregoing, on
or before [**] and [**] of each year during the term of this Agreement, Licensee shall provide to COH a written report setting forth,
in reasonable detail, its activities and achievements with respect to the development and commercialization of Licensed Products and Licensed
Services during the preceding [**], including activities relating to the achievement of the Diligence Milestones (the “[**] Report”).
The Designated Representatives shall meet in person [**] to present and discuss the current [**] Report at such location and date as mutually
agreed. Each Party shall be responsible for all expenses incurred by its Designated Representative in the participation in such annual
meetings.

 

ARTICLE 3: LICENSE GRANTS

 

3.1            Grant
of Rights. COH hereby grants to Licensee an exclusive royalty-bearing right and license under the Patent Rights to make, have
made, use, offer for sale, sell and import Licensed Products and to perform Licensed Services, in the Field, in the Territory. The foregoing
grant of rights shall be subject to: [**].

 

3.2            No
Implied Licenses. Licensee acknowledges that the licenses granted in this Agreement are limited to the scope expressly granted
and that, subject to the terms and conditions of this Agreement, all other rights under all Patent Rights and other intellectual property
rights Controlled by COH are expressly reserved to COH.

 

3.3            Sublicensing.
Licensee shall have the right to sublicense its rights hereunder without the consent of COH [**]. The terms and conditions of each sublicense
of Licensee’s rights hereunder shall be consistent with this Agreement. A true and complete copy of each sublicense of Licensee’s
rights hereunder, as well as any amendment thereto, shall be delivered to COH within [**] of the effective date of each such sublicense
or amendment, provided that COH shall treat the contents of each such sublicense agreement and amendment as Licensee Confidential
Information. Sublicensees shall also have the right to further sublicense their rights, and so on through multiple sub-license levels.

 

    9

     

    

 

EXECUTION COPY

 

3.4            Documentation
of Licensed Services. Licensee and its Sublicensees shall provide Licensed Services only pursuant to one or more written agreements
which set forth, in reasonable detail, all consideration due to Licensee for the provision of such services. Licensee shall provide a
true and complete copy of each such agreement to COH promptly following the effective date of such agreement, provided that COH
shall treat the contents of each such agreement as Licensee Confidential Information.

 

3.5            Designated
Affiliates.

 

3.5.1        Notice
of Designated Affiliate. Licensee shall have the right, from time-to-time during the Term, to designate any of its Affiliates
as “Designated Affiliates” by written notice to COH. Such notice shall be accompanied by a Designated Affiliate Agreement
that has been completed, duly executed by such Designated Affiliate and executed as acknowledged by Licensee. COH shall execute and deliver
such Designated Affiliate Agreement promptly after receipt and a reasonable opportunity to review the agreement for conformity with the
form attached hereto as Exhibit C and the other requirements of this Agreement. Such designation shall become effective upon the
execution of the Designated Affiliate Agreement and the payment of the fee described in Section 4.2.2.

 

3.5.2        Field.
Licensee and COH hereby acknowledge and agree that certain rights and licenses to activities and uses that are included within the field
will be conveyed to each Designated Affiliate as and to the extent provided for in, and during the term of, the relevant Designated Affiliate
Agreement (the “Designated Affiliate Field”) and that the Field and the scope of rights granted hereunder to Licensee
shall both automatically be amended and restated in their entirety to exclude such Designated Affiliate Field.

 

ARTICLE 4: PAYMENTS

 

4.1            Up-Front
Payment. In consideration for the license to the Patent Rights, COH acknowledges that Licensee satisfied its obligation to pay
to COH a one-time non-refundable license fee of $[**] within [**] after the Original Effective Date.

 

4.2            License
Maintenance Fee; Designated Affiliate Fee.

 

4.2.1        License
Maintenance Fee. Within [**] in consideration for the license to the Patent Rights. The license maintenance fees paid in a given
License Year shall be applied as credit against royalties otherwise due to COH pursuant to Section 4.6, below, during the License
Year in which payment was made but may not be carried over and applied as credit against royalties due in subsequent years.

 

4.2.2        Designated
Affiliate Fee. Licensee shall pay to COH a fee of [**] dollars ($[**]) within [**] after providing notice to COH under Section 3.5.1
that Licensee is designating a Designated Affiliate. Such fee shall be payable each time that Licensee provides a notice of designation
under Section 3.5.1.

 

4.3            Sale
of Licensee Business. Upon the first Change of Control of Licensee or Parent, Licensee shall pay COH a non-refundable fee of $500,000.
Notwithstanding the foregoing, the foregoing payment shall [**].

 

    10

     

    

 

EXECUTION COPY

 

4.4            Stock
Grant. COH acknowledges that it received 228,184 common units of Parent in exchange for [**] shares of Licensee’s Common
Stock that had been issued to COH in connection with execution of the Original Agreement.

 

4.5            Diligence
Milestone Payments. Within [**] of the occurrence of each “Diligence Milestone Event” set forth below,
for each of the first three Licensed Products or Licensed Services to reach the applicable Diligence Milestone Event, whether achieved
by Licensee, its Affiliate (excluding Designated Affiliates) or a Sublicensee, Licensee shall pay COH or its designee the amount indicated
below for each Licensed Product or Licensed Service reaching the applicable Diligence Milestone Event.

 

	Diligence Milestone Event	Amount Due
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]

 

In the event that any Diligence Milestone Event
is met with respect to any of the first three Licensed Products or Licensed Services prior to the satisfaction of any prior Diligence
Milestone Event with respect to the same Licensed Product or Licensed Service, then Licensee shall also pay the amount due for occurrence
of all prior Diligence Milestone Events not previously paid upon meeting the applicable Diligence Milestone Event [**].

 

For
the sake of clarity, Diligence Milestone Payments made to COH by all Designated Affiliates acting under Designated Affiliate Agreements
shall be taken into account in determining whether Licensee has satisfied its obligation to make Diligence Milestone Payments to COH for
the first three Licensed Products or Licensed Services to reach the applicable Diligence Milestone Event.

 

Notwithstanding anything to the contrary in this
Agreement, each Diligence Milestone Payment set forth in the table above shall not be due more than once per biological target (hence
Diligence Milestone Payments are not due on back-up molecules advanced by Licensee or Sublicensee until such back-up molecule has advanced
to a Diligence Milestone Event not previously attained by a molecule previously being developed by Licensee or its Sublicensees acting
at the same biological target and for which the applicable Diligence Milestone Payment has already been paid).

 

4.6            Royalties.
Licensee shall pay to COH or its designee royalties in an amount equal to:

 

    11

     

    

 

EXECUTION COPY

 

4.6.1         [**]%)
percent of annual Net Sales of Licensed Products and Licensed Services up to and including $[**] in annual aggregate Net Sales;

 

4.6.2         [**]%)
percent of annual Net Sales of Licensed Products and Licensed Services that exceed $[**] in annual aggregate Net Sales;

 

Royalties shall be paid on a Licensed Product-by-Licensed
Product, Licensed Service-by-Licensed Service and country-by-country basis until the expiration in each country of the last to expire
of the Valid Claims in such country Covering Licensed Products or Licensed Services, as the case may be.

 

4.7            Sublicense
Revenues. Licensee shall pay to COH:

 

4.7.1         The
applicable percentage share of all Sublicense Revenues given in Section 4.7.2 below in connection with the grant of a sublicense
of the Patent Rights to a Sublicensee, in each case, within [**] after payment is received from the relevant Sublicensee.

 

4.7.2         If
the sublicense grant to the Sublicensee occurs [**], then [**]%. If the sublicense grant to the Sublicensee occurs [**], then [**]%. If
the sublicense grant to the Sublicensee occurs [**], then [**]%. If the sublicense grant to the Sublicensee occurs [**], then [**]%.

 

4.7.3         If
Sublicense Revenues are not in cash or cash equivalents, the percentage share payable to COH pursuant to this Section 4.7 shall be
due, in the form received by Licensee, unless otherwise agreed by the Parties. In the event that COH requests to be paid the applicable
percentage share of Sublicense Revenues in the form of a cash equivalent, Licensee shall reasonably consider such request, taking into
consideration its ability to pay such amounts at such time.

 

4.8            Royalty
Offsets. If, [**] it is necessary to pay to a Third Party other than a Sublicensee consideration (whether in the form of a royalty
or otherwise) for the right to make, have made, use, sell, offer for sale or import a specific Licensed Product or specific Licensed Service
in a given jurisdiction, and if the aggregate royalty rates of any and all royalties payable to such Third Party licensors when combined
with the royalty rate payable to COH exceeds [**] percent ([**]%) in the case of Net Sales of the specific Licensed Product or specific
Licensed Service, then Licensee shall have the right with respect to any period for which royalties are due (i.e., a calendar quarter
or calendar year) to set off [**]%) percent of the aggregate royalties otherwise payable with respect to such period and such jurisdiction
to such Third Party licensors against royalties that would otherwise be due to COH hereunder with respect to such period and jurisdiction;
provided, however, that under no circumstances shall the royalty offsets permitted in this Section 4.8 result in the
reduction of the effective adjusted royalty rate in any period for which payment is due and in any jurisdiction pursuant to Section 4.6,
above, be less than [**]%) percent of Net Sales).

 

4.9            Timing
of Royalty Payments. Royalty payments due under Section 4.6, above, shall be paid [**] within [**] in which aggregate Net
Sales across all Licensed Products and Licensed Services reach $[**]. Thereafter, all royalty payments due under Section 4.6 shall
be paid [**], within [**].

 

    12

     

    

 

EXECUTION COPY

 

4.10          No
Deductions from Payments. Subject to Section 4.7 above, Licensee is solely responsible for payment of any fee, royalty or
other payment due to any Third Party not a Sublicensee in connection with the research, development, manufacture, distribution, use, sale,
import or export of a Licensed Product or Licensed Service and except as set forth in Section 4.8 above, Licensee shall not have
the right to set off any amounts paid to such a Third Party, including fee, royalty or other payment, against any amount payable to COH
hereunder.

 

4.11          Single
Royalty. Only a single royalty payment shall be due and payable on Net Sales of a Licensed Product or performance of a Licensed
Service, regardless if such Licensed Product or Licensed Service is Covered by more than one Valid Claim.

 

4.12          Payments
Under Single License Only. Notwithstanding any provision in this Agreement or in the other license agreement of even date herewith
between the Parties to the contrary, (i) Research Expenses shall be aggregated across both such license agreements and include expense
within the defined parameters incurred by Licensee, Sublicensees and their respective Affiliates, (ii) diligence milestone payments
and royalties for a given Licensed Product or Licensed Services shall be payable only once across both such license agreements, and (iii) the
sublicense revenue share (under Section 4.7) shall be payable only once if a sublicense is granted under each such license agreement
to a single Sublicensee.

 

4.13          Research
Funding. On the Original Effective Date, Licensee and COH with Dr. Williams, as the principal investigator, entered into
the sponsored research agreement (the “Research Agreement”) attached hereto as Exhibit B.

 

ARTICLE 5: REPORTS, AUDITS AND FINANCIAL
TERMS

 

5.1            Royalty
Reports. Within [**] after [**] in which a royalty payment under Article 4 is required to be made, Licensee shall send to
COH a report of Net Sales of the Licensed Products and Licensed Services for which a royalty is due, which report sets forth for such
[**] the following information, on a Licensed Product-by-Licensed Product, Licensed Service-by-Licensed Service and country-by-country
basis: (i) total Net Sales, (ii) total gross sales of Licensed Products and Licensed Services, (iii) the quantity of each
Licensed Products sold and Licensed Services performed, (iv) the exchange rate used to convert Net Sales from the currency in which
they are earned to United States dollars; and (v) the total royalty payments due.

 

5.2            Additional
Financial Terms.

 

5.2.1         Currency.
All payments to be made under this Agreement shall be made in United States dollars, unless expressly specified to the contrary herein.
Net Sales outside of the United States shall be first determined in the currency in which they are earned and shall then be converted
into an amount in United States dollars. All currency conversions shall use the conversion rate reported by Reuters, Ltd. on the
last Business Day of the calendar quarter for which such payment is being determined.

 

5.2.2         Payment
Method. Amounts due under this Agreement shall be paid in immediately available funds, by means of wire transfer to an account
identified by COH.

 

    13

     

    

 

EXECUTION COPY

 

5.2.3         Withholding
of Taxes. Licensee may withhold from payments due to COH amounts for payment of any withholding tax that is required by law to
be paid to any taxing authority with respect to such payments. Licensee shall provide to COH all relevant documents and correspondence,
and shall also provide to COH any other cooperation or assistance on a reasonable basis as may be necessary to enable COH to claim exemption
from such withholding taxes and to receive a full refund of such withholding tax or claim a foreign tax credit. Licensee shall give COH
proper evidence from time to time as to the payment of such tax. The Parties shall cooperate with each other in seeking deductions under
federal and state tax laws and any double taxation or other similar treaty or agreement from time to time in force.

 

5.2.4         Late
Payments. Any amounts not paid on or before the date due under this Agreement are subject to interest from the date due through
and including the date upon which payment is received. Interest is calculated, over the period between the date due and the date paid,
at a rate equal to [**] percentage point ([**]%) over the “bank prime loan” rate, as such rate is published in the U.S. Federal
Reserve Bulletin H.15 or successor thereto on the last Business Day of the applicable calendar quarter prior to the date on which such
payment is due.

 

5.2.5         Blocked
Currency. If, at any time, legal restrictions prevent the prompt remittance of part or all royalties with respect to any country
where a Licensed Product is sold or Licensed Service provided, payment shall be made through such lawful means or methods as Licensee
may determine. When in any country, the law or regulations prohibit both the transmittal and deposit of royalties or other payments, Licensee
shall continue to report all such amounts, but may suspend payment for as long as such prohibition is in effect. As soon as such prohibition
ceases to be in effect, all amounts that would have been obligated to be transmitted or deposited but for the prohibition, together with
accrued interested thereon, shall promptly be transmitted to COH.

 

5.3            Accounts
and Audit.

 

5.3.1         Records.
Licensee shall keep, and shall require that each Sublicensee keep, full, true and accurate books of account containing the particulars
of, as the case may be, its Research Expenses, Net Sales and the calculation of royalties. Licensee and its Sublicensees shall each keep
such books of account and the supporting data and other records at its principal place of business. Such books and records must be maintained
available for examination in accordance with this Section 5.3.1 for [**] after the end of the calendar year to which they pertain,
and otherwise as reasonably required to comply with GAAP.

 

5.3.2         Appointment
of Auditor. COH may appoint an internationally-recognized independent accounting firm reasonably acceptable to Licensee to inspect
the relevant books of account of Licensee and its Sublicensees to verify any Research Expenses, to the extent relied upon by Licensee
to achieve a Diligence Milestone, reports or statements provided, or amounts paid or invoiced (as appropriate), by Licensee or its Sublicensees.

 

5.3.3         Procedures
for Audit. COH may exercise its right to have Licensee’s and its Sublicensees’ relevant records examined only during
the [**] period during which Licensee is required to maintain records, no more than [**]. Licensee and its Sublicensees are required to
make records available for inspection only during regular business hours, only at such place or places where such records are customarily
kept, and only upon receipt of at least [**] advance notice from COH.

 

    14

     

    

 

EXECUTION COPY

 

5.3.4         Audit
Report. The independent accountant will be instructed to provide to COH an audit report containing only its conclusions and methodology
regarding the audit, and specifying whether the amounts paid were correct or the Research Expenses incurred were correctly reported in
connection with the achievement of a Diligence Milestone, and, if incorrect, the amount of any underpayment, any overpayment or any Research
Expenses incorrectly reported.

 

5.3.5         Underpayment
and Overpayment. After review of the auditor’s report: (i) if there is an uncontested underpayment by Licensee for
all of the periods covered by such auditor’s report, then Licensee shall pay to COH the full amount of that uncontested underpayment,
and (ii) if there is an uncontested overpayment for such periods, then COH shall provide to Licensee a credit against future payments
(such credit equal to the full amount of that overpayment), or, if Licensee is not obligated to make any future payments, then COH shall
pay to Licensee the full amount of that overpayment. Contested amounts are subject to dispute resolution under Article 12. If the
total amount of any such underpayment (as agreed to by Licensee or as determined under Article 12) exceeds [**]%) percent of the
amount previously paid by Licensee for the period subject to audit, then Licensee shall pay the reasonable costs for the audit. Otherwise,
all costs of the audit shall be paid by COH.

 

ARTICLE 6: LICENSEE COVENANTS

 

6.1            Licensee
covenants and agrees that in conducting activities contemplated under this Agreement, it shall comply in all material respects with all
applicable laws and regulations including, without limitation, those related to the manufacture, use, labeling importation and marketing
of Licensed Products and Licensed Services.

 

ARTICLE 7:
INTELLECTUAL PROPERTY; PATENT PROSECUTION, MAINTENANCE AND ENFORCEMENT.

 

7.1            Patent
Prosecution, Maintenance and Enforcement.

 

(a)            As
of the Original Effective Date, Licensee assumed and became responsible for the preparation, filing, prosecution, and maintenance of all
Patent Rights in the name of COH at Licensee’s own expense, using Licensee counsel reasonably acceptable to COH. Licensee will timely
provide COH with copies of all relevant documentation relating to such prosecution and COH shall keep such information confidential. Licensee’s
counsel shall take instructions only from Licensee and COH’s counsel shall take instructions only from COH.

 

    15

     

    

 

EXECUTION COPY

 

(b)            Promptly
following the end of each [**] or upon request of COH, Licensee will provide COH with an update and details regarding the filing, prosecution
and maintenance status of the Patent Rights. Licensee shall provide COH with drafts of all proposed filings (including, without limitation,
the initial application as well as any material correspondence related to any filings) in a manner that allows COH a reasonable opportunity
to review and comment before any such filing is made or due but in no event, except when impossible, less than [**] prior to any filing
deadline. Licensee will consider all of, and incorporate to the extent commercially reasonable for Licensee’s conduct of its business,
COH’s suggestions, recommendations and instructions concerning the preparation, filing, prosecution, defense and maintenance of
the Patent Rights (including without limitation any suggestion or recommendation to alter or expand or limit the scope, content and/or
claims of any such application), and, to the extent otherwise possible, will undertake the preparation, filing, prosecution and defense
of the Patent Rights in a way that is intended to reasonably optimize the scope and enforceability of the Patent Rights. COH shall cooperate
with Licensee in the preparation, filing, prosecution, and maintenance of the Patent Rights by disclosing such information as may be necessary
and by promptly executing such documents as Licensee may request to effect such efforts. COH shall secure, and upon request provide to
Licensee, assignments from all employees and other individuals necessary to grant the rights, licenses and privileges granted in this
Agreement. The aforementioned provisions of this subparagraph are collectively the “Cooperation Provisions”. For clarity,
(i) Licensee may not use cost or expense as a basis to deem any proposed COH claim or application commercially unreasonable, provided
COH is willing to bear any increased cost or expense, in which case Licensee shall not be entitled to the benefits of any such claim or
application unless COH’s costs are reimbursed and (ii) if Licensee deems any COH claim or application commercially unreasonable
due to cost or expense, COH shall be entitled to require Licensee to file continuation, divisional or other independent applications to
be prosecuted and maintained by COH at its cost and expense independent of Licensee and which shall be outside the scope of the rights
licensed pursuant to this Agreement.

 

(c)            Licensee
will not unreasonably refuse to amend any patent application in the Patent Rights to include claims reasonably requested by COH to protect
the products contemplated to be sold by Licensee under this Agreement.

 

(d)            Each
Party shall promptly provide written notice to the other in the event it becomes aware of any actual or probable infringement of any of
the Patent Rights in or relevant to the Field or of any Third Party claim regarding the enforceability or validity of any Patent Rights
(“Infringement Notice”). Licensee shall, in cooperation with COH, use reasonable efforts to terminate infringement
without litigation.

 

(e)            If
infringing activity has not been abated within [**] following the date the Infringement Notice takes effect, then Licensee may, following
consultation with COH, in its sole discretion and at its sole expense, take action against any alleged infringer or in defense of such
any claim, provided, that, Licensee has exclusive rights under this Agreement. Any recovery obtained by Licensee as the result of legal
proceedings initiated and paid for by Licensee pursuant to this subsection (e), after deduction of Licensee’s reasonable out-of-pocket
expenses incurred in securing such recovery, shall be deemed to be Net Sales of Licensed Products and/or Licensed Services in the calendar
quarter in which such recovery was received and royalties shall be due and payable thereon accordingly.

 

(f)             If
COH is involuntarily joined in a suit initiated by Licensee, then the Licensee will pay any out-of-pocket costs reasonably incurred by
COH arising out of such suit, including but not limited to, reasonable legal fees of counsel that COH selects and retains to represent
it in the suit.

 

    16

     

    

 

EXECUTION COPY

 

(g)            In
the event that Licensee declines either to cause such infringement to cease (e.g., by settlement or injunction) or to initiate and thereafter
diligently maintain legal proceedings against the infringer other than as part of a mutually agreed upon bona fide strategy, developed
with the guidance of outside patent counsel, to preserve the Patent Rights, COH may, in its sole discretion and at its sole expense, take
action against such alleged infringer or in defense of any Third Party claim. Any recovery obtained by COH as the result of any such legal
proceedings shall be for the benefit of COH only. Failure on the part of Licensee to prosecute any such infringement for which it has
standing to prosecute, absent a settlement between Licensee and such infringing Third Party, shall be grounds for conversion of the exclusive
licenses granted to Licensee hereunder to co-exclusive licenses with Licensee and with such infringing Third Party(ies), with respect
to the country in which such infringement occurs, at the option of COH, provided, however, that COH may only subsequently enter into subsequent
license agreements with such infringing Third Party(ies) (i.e., not any other Third Party) and, provided further, that such license(s) shall
not contain running royalty rates lower than the rates specified in this Agreement nor grant such third parties the right to sublicense.
Licensee agrees to execute any and all necessary documents and perform such acts as are reasonably requested by COH in order to effect
such grant to such Third Party. All fees, royalties, payments and any other consideration to be paid by that Third Party under the co-exclusive
license shall be paid to COH.

 

7.2            Trademarks.
Licensee shall be responsible for the selection, registration, maintenance, and defense of all trademarks for use in connection with the
sale or marketing of Licensed Products and Licensed Services in the Field in the Territory (the “Marks”), as well as
all expenses associated therewith. All uses of the Marks by Licensee or a Sublicensee shall comply in all material respects with all applicable
laws and regulations (including those laws and regulations particularly applying to the proper use and designation of trademarks in the
applicable countries). Licensee shall not, without COH’s prior written consent, use any trademarks or house marks of COH (including
the COH corporate name), or marks confusingly similar thereto, in connection with Licensee commercialization of Licensed Products or Licensed
Services under this Agreement in any promotional materials or applications or in any manner implying an endorsement by COH of Licensee
or the Licensed Products or Licensed Services. Licensee shall own all Marks.

 

7.3            Challenge
to the Patent Rights by Licensee.

 

(a)            COH
may terminate this Agreement and, notwithstanding Section 3.3, above, all Sublicenses issued hereunder, upon written notice to Licensee
in the event that Licensee or any of its Affiliates (excluding Designated Affiliates) or Sublicensees directly or indirectly asserts a
Patent Challenge. “Patent Challenge” means any challenge in a legal or administrative proceeding to the patentability,
validity or enforceability of any of the Patent Rights (or any claim thereof), including by: (a) filing or pursuing a declaratory
judgment action in which any of the Patent Rights is alleged to be invalid or unenforceable; (b) citing prior art against any of
the Patent Rights, filing a request for or pursuing a re-examination of any of the Patent Rights (other than with COH’s written
agreement), or becoming a party to or pursuing an interference; or (c) filing or pursuing any re-examination, opposition, cancellation,
nullity or other like proceedings against any of the Patent Rights; but excluding any challenge raised as a defense against a claim, action
or proceeding asserted by COH against Licensee, its Affiliates (excluding Designated Affiliates) or Sublicensees. In lieu of exercising
its rights to terminate under this Section 7.3(a) COH may elect upon written notice to increase the payments due under all of
Article 4 by [**] percent ([**]%), which election will be effective retroactively to the date of the commencement of the Patent Challenge.
Licensee acknowledges and agrees that this Section 7.3(a) is reasonable, valid and necessary for the adequate protection of
COH’s interest in and to the Patent Rights, and that would not have granted to Licensee the licenses under those Patent Rights,
without this Section 7.3(a). COH will have right at any time in its sole discretion to strike this Section 7.3(a) (or any
portion thereof) from this Agreement, and COH will have no liability whatsoever as a result of the presence or absence of this Section 7.3(a) (or
any struck portion thereof).

 

    17

     

    

 

EXECUTION COPY

 

(b)            If
COH obtains a final non-appealable judgment upholding the validity and enforceability of the challenged Patent Rights and finding at least
one claim of such Patent Rights to be infringed by Licensee or any one of its Affiliates (excluding Designated Affiliates) or Sublicensees,
Licensee shall reimburse COH all of its attorneys’ fees and expenses expended in connection with defending such lawsuit or other
proceeding.

 

7.4            Payment
of COH Patent Expenses.

 

(a)            The
Parties acknowledge that, prior to the Original Effective Date, COH incurred [**] with respect to [**] of the Patent Rights. In consideration
of such [**] by COH, Licensee shall [**].

 

(b)            In
the event that COH, in its reasonable judgment, makes an initial filing to maintain the patentability of a Subject Invention as defined
in the Research Agreement set forth in Exhibit B, Licensee shall reimburse COH for all reasonable costs incurred by COH in connection
therewith.

 

7.5            Marking.
Licensee and its Sublicensees shall mark all Licensed Products and all materials related to Licensed Services in such a matter as to conform
with the patent laws of the country to which such Licensed Products are shipped or in which such products are sold and such Licensed Services
performed.

 

ARTICLE 8: TERM AND TERMINATION

 

8.1            Term
and Expiration of Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and, notwithstanding
any other provision of this Agreement, unless sooner terminated by mutual agreement or pursuant to any other provision of this Agreement,
this Agreement shall expire on a country-by-country basis and on a Patent Right-by-Patent Right basis on the later to occur of: (a) the
expiration of the last to expire of any of the Patent Rights in such country (or if no patent issues, until the last patent application
in Patent Rights is abandoned), and (b) the date on which the last of the remaining obligations under this Agreement between the
Parties with respect to the payment of milestones or royalties with respect to Licensed Products and Licensed Services have been satisfied
(such expiry of the Term hereinafter referred to as “Expiration”).

 

8.2            Termination.

 

8.2.1         Material
Breach. Either Party may terminate this Agreement prior to its Expiration for any material breach by the other Party, provided
that the Party seeking to terminate shall have first given the breaching Party notice of such material breach with reasonable particulars
of the material breach, and the Party receiving the notice of the material breach shall have failed to cure that material breach within
[**] after the date of receipt of such notice.

 

    18

     

    

 

EXECUTION COPY

 

8.2.2         Bankruptcy.
COH shall have the right to terminate this Agreement prior to its Expiration upon notice to Licensee, in the event that: (i) Licensee
seeks protection of any bankruptcy or insolvency law other than with the prior consent of City of Hope, or (ii) a proceeding in bankruptcy
or insolvency is filed by or against Licensee and not withdrawn, removed or vacated within  [**] of such filing, or there is adjudication
by a court of competent jurisdiction that Licensee is bankrupt or insolvent.

 

8.2.3         Termination
at Will by Licensee. Licensee shall have the right to terminate this Agreement prior to its Expiration upon notice to COH without
cause, effective no fewer than 30 days following the date of such notice.

 

8.2.4         Termination
bv COH for Breach-Based Termination of the Research Agreement. COH shall have the right to terminate this Agreement following
COH’s termination of the Research Agreement (i) pursuant to Section 11.2 of the Research Agreement for Licensee’s
failure to pay amounts due thereunder or (ii) pursuant to Section 11.3 of the Research Agreement for Licensee’s uncured
material breach thereof; provided that, in the event of any such termination of the Research Agreement by COH, Licensee shall provide
written notice to COH of such termination, and COH may terminate this Agreement at any time after such termination of the Research Agreement,
but in no event later than [**] after the receipt of such notice from Licensee.

 

8.3            Effect
of Termination.

 

8.3.1         Upon
any termination of this Agreement pursuant to Section 8.2 (but for clarity, not in the case of its Expiration), all rights and licenses
granted to Licensee under Article 3 and all sublicenses granted by Licensee except as provided below shall immediately terminate
on and as of the effective date of termination as provided in Section 8.2, except that (a) Licensee and its Sublicensees shall
have the right to continue to sell Licensed Products manufactured prior to the effective date of such termination until the sooner of:
(i) [**] after the effective date of termination, or (ii) the exhaustion of Licensee’s or Sublicensees’ inventory
of Licensed Products; and (b) each sublicense granted in compliance with this Agreement, provided that the Sublicensee is not then
in material default of its obligations under the sublicense, will remain in effect, and each Sublicensee thereafter will be deemed a
direct licensee of COH, and each such sublicense agreement will be considered to be a direct license agreement between COH and the Sublicensee,
mutatis mutandis, provided that COH will not be bound to: (1) perform any obligations set forth in any such sublicense agreement
that extend beyond the obligations of COH set forth in this Agreement, or (2) accept compensation under any such sublicense agreement
that taken as a whole in COH’s reasonable discretion would be less than the compensation payable to COH in respect of such Sublicensee’s
activities pursuant to this Agreement.

 

    19

     

    

 

EXECUTION COPY

 

8.3.2         Upon
termination of this Agreement pursuant to Section 8.2 (but for clarity, not in the case of its Expiration):

 

(a)            Each
Party shall promptly return to the other Party all relevant records and materials in its possession or control containing or comprising
the other Party’s Confidential Information and to which the Party does not retain rights hereunder.

 

(b)            Licensee
shall discontinue making any representation regarding its status as a licensee of COH for Licensed Products and Licensed Services. Subject
to Section 8.3.1, above, Licensee shall cease conducting any activities with respect to the marketing, promotion, sale or distribution
of Licensed Products and Licensed Services.

 

8.3.3         Termination
of this Agreement through any means and for any reason pursuant to Section 8.2 (but for clarity, not in the case of its Expiration),
shall not relieve the Parties of any obligation accruing prior thereto, including the payment of all sums due and payable, and shall be
without prejudice to the rights and remedies of either Party with respect to any antecedent breach of any of the provisions of this Agreement.

 

8.4            Designated
Affiliate Agreements. The termination or expiration of this Agreement shall have no effect on the continued effectiveness of any
Designated Affiliate Agreements. The termination of any Designated Affiliate Agreement shall cause the reversion of the rights granted
thereunder to Licensee under this Agreement as if such Designated Affiliate Agreement had never been entered into provided that Licensee
assumes in writing any unfulfilled obligations or liabilities of the relevant Designated Affiliate under such Designated Affiliate Agreement.

 

8.5            Survival.
Sections 4.9, 5.1, 5.2, 5.3, 8.3, 8.4, 8.5, Article 10, Article 11, Article 12, Sections 14.1-14.11 and Sections 14.14-14.15
shall survive termination of this Agreement for any reason pursuant to Section 8.2 and Expiration pursuant to Section 8.1.

 

ARTICLE 9: REPRESENTATIONS AND WARRANTIES

 

9.1            Mutual
Representations and Warranties. COH and Licensee each represents and warrants as follows:

 

9.1.1         It
has the right and authority to enter into this Agreement and all action required to be taken on its behalf, its officers, directors, partners
and stockholders necessary for the authorization, execution, and delivery of this Agreement and, the performance of all of its obligations
hereunder, and this Agreement, when executed and delivered, will constitute valid and legally binding obligations of such Party, enforceable
in accordance with its terms, subject to: (i) laws limiting the availability of specific performance, injunctive relief, and other
equitable remedies; and (ii) bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws now
or hereafter in effect generally relating to or affecting creditors’ rights generally;

 

9.1.2         Entry
into this Agreement will not constitute a breach of any other agreement to which it is party;

 

9.1.3         It
has read this Agreement, with assistance from its counsel of choice. It understands all of this Agreement’s terms. It has been given
a reasonable amount of time to consider the contents of this Agreement before each Party executed it. It agrees that it is executing this
Agreement voluntarily with full knowledge of this Agreement’s legal significance; and

 

    20

     

    

 

EXECUTION COPY

 

9.1.4         It
has made such investigation of all matters pertaining to this Agreement that it deems necessary, and does not rely on any statement, promise,
or representation, whether oral or written, with respect to such matters other than those expressly set forth herein. It agrees that it
is not relying in any manner on any statement, promise, representation or understanding, whether oral, written or implied, made by any
Party, not specifically set forth in this Agreement. It acknowledges that, after execution of this Agreement, it may discover facts different
from or in addition to those which it now knows or believes to be true. Nevertheless, it agrees that this Agreement shall be and remain
in full force and effect in all respects, notwithstanding such different or additional facts.

 

9.2            Representations
and Warranties of Licensee. Licensee represents and warrants that as of the Original Effective Date:

 

9.2.1         All
authorizations necessary for the issuance of the COH Shares issuable to COH pursuant to Section 4.4(a) of the Original Agreement,
were obtained;

 

9.2.2         no
consent, approval, order, or authorization of, or registration, qualification, designation, declaration, or filing with, any federal,
state, or local governmental authority on the part of Licensee was required in connection with the offer, sale, or issuance of the COH
Shares or the consummation of any other transaction contemplated hereby, except for the following: (i) the filing of a notice of
exemption pursuant to Section 25102(f) of the California Corporate Securities Law of 1968, as amended, which was filed by Licensee
promptly following the Original Effective Date; and (ii) the compliance with other applicable state securities laws, which compliance
will have occurred within the appropriate time periods therefor. The offer, sale, and issuance of the COH Shares in conformity with the
terms of the Original Agreement are exempt from the registration requirements of Section 5 of the Act, and from the qualification
requirements of Section 25110 of the California Securities Law, and Licensee, nor any authorized agent acting on its behalf will
take any action hereafter that would cause the loss of such exemptions;

 

9.2.3         The
sale of the COH Shares was not and will not be subject to any preemptive rights or rights of first refusal that have not been properly
waived or complied with;

 

9.2.4         The
COH Shares, when issued, sold and delivered in accordance with the terms of the Original Agreement for the consideration expressed therein,
were duly and validly issued, fully paid and nonassessable and free of restrictions on transfer, other than restrictions on transfer under
applicable state and federal securities laws;

 

9.2.5         As
of the Original Effective Date, the authorized capital stock of Licensee consisted of 10,000,000 shares of Common Stock, [**]. As such
the [**] shares issued to COH pursuant to the Original Agreement and the [**] shares issued to COH (or its designees) pursuant to a second
license agreement between the parties executed on or about even date to the Original Agreement together [**] on the date such shares were
issued. As of the Original Effective Date, Licensee had not reserved any equity securities for issuance pursuant to Licensee’s equity
incentive compensation plans. All issued and outstanding shares of Licensee were duly authorized and validly issued and were fully paid
and nonassessable. Other than the outstanding Common Stock, including the COH Shares, there were no other outstanding rights, options,
warrants, preemptive rights, rights of first refusal, or similar rights for the purchase or acquisition from Licensee of any securities
of Licensee nor any commitments to issue or execute any such rights, options, warrants, preemptive rights or rights of first refusal.
The respective rights, preferences, privileges, and restrictions of the Common Stock were solely as stated in Licensee’s certificate
of incorporation, a true and correct copy of which was delivered to COH prior to the Original Effective Date;

 

    21

     

    

 

EXECUTION COPY

 

9.2.6         Licensee
was not in violation or default of any provision of its certificate of incorporation or bylaws on the Original Effective Date or on the
date of issuance of the COH Shares, and;

 

9.2.7         Prior
to the Original Effective Date, Licensee had not entered into any agreements pursuant to which the Patent Rights had been sublicensed.

 

9.3            Representations
and Warranties of COH. COH represents and warrants that, as of the Original Effective Date, to the actual knowledge of the Director
of its Office of Technology Transfer without independent inquiry, COH has the full power and authority to grant the rights, licenses and
privileges granted herein.

 

9.4            Exclusions.
Nothing in this Agreement is or shall be construed as:

 

9.4.1         A
warranty or representation by COH as to the validity or scope of any claim or patent or patent application within the Patent Rights;

 

9.4.2         A
warranty or representation by COH that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement
is or will be free from infringement of any patent rights or other intellectual property right of any Third Party;

 

9.4.3         A
grant by COH, whether by implication, estoppel, or otherwise, of any licenses or rights under any patents other than Patent Rights as
defined herein, regardless of whether such patents are dominant or subordinate to Patent Rights;

 

9.4.4         An
obligation on COH to bring or prosecute any suit or action against a Third Party for infringement of any of the Patent Rights;

 

9.4.5         An
obligation to furnish any know-how not provided in Patent Rights; or

 

9.4.6         A
representation or warranty of the ownership of the Patent Rights other than as set forth in Section 9.3, above.

 

9.5            DISCLAIMER.
EXCEPT AS EXPRESSLY STATED IN SECTIONS 9.1 AND 9.3 OF THIS AGREEMENT, NO WARRANTY IS GIVEN WITH RESPECT TO THE PATENT RIGHTS, EXPRESS
OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND HIE PARTIES SPECIFICALLY DISCLAIM ANY EXPRESS OR IMPLIED
WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF THE PATENT RIGHTS OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY
OR OTHER RIGHTS OF ANY THIRD PARTY. THE WARRANTIES SET FORTH IN SECTIONS 9.1 AND 9.3 ABOVE ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS
OR IMPLIED, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, VALIDITY,
NON-INFRINGEMENT AND ALL SUCH OTHER WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED.

 

    22

     

    

 

EXECUTION COPY

 

ARTICLE 10: INDEMNIFICATION

 

10.1          Indemnification
by Licensee. Licensee shall defend, indemnify and hold harmless COH, its Affiliates, and their respective officers, directors,
shareholders, employees and agents (“COH Indemnitees”) from and against any and all Third Party liabilities, claims,
suits, and expenses, including reasonable attorneys’ fees (collectively, “Losses”), arising out of or are in
any way attributable to: (i) the material breach of any representation or warranty made by Licensee under this Agreement, (ii) the
research, development, marketing, approval, manufacture, packaging, labeling, handling, storage, transportation, use, distribution, promotion,
marketing or sale of Licensed Products or Licensed Services by or on behalf of Licensee, any of its Affiliates (excluding Designated Affiliates)
or a Sublicensee or any other exercise of rights under this Agreement or pursuant to any sublicense, or (iii) the negligence, willful
misconduct or failure to comply with applicable law by a Licensee Indemnitee or Sublicensee.

 

10.2          Procedure.
The indemnities set forth in Section 10.1 are subject to the condition that COH shall forthwith notify Licensee of a liability, claim,
suit, action or expense and that Licensee defend and control any proceedings with COH being permitted to participate at its own expense
(unless there shall be a conflict of interest which would prevent representation by joint counsel, in which event Licensee shall pay for
COH’s counsel): provided, that, Licensee may not settle the liability, claim, suit, action or expense, or otherwise
admit fault of COH or consent to any judgment, without the written consent of COH (such consent not to be unreasonably withheld). Notwithstanding
the foregoing, no delay in the notification of the existence of any claim of Loss shall cause a failure to comply with this Section 10.2
as long as such delay shall not have materially impaired the rights of Licensee.

 

10.3          Insurance.

 

(a)            Within
[**] following the first equity or debt financing with net proceeds to Licensee or Parent of greater than $[**], Licensee shall procure
at its sole expense (or shall be covered under a policy maintained by an Affiliate) and provide to COH evidence of comprehensive or commercial
general liability insurance (contractual liability included) with limits of at least: (i) each occurrence, $[**]; (ii) products/completed
operations aggregate, $[**]; (iii) personal and advertising injury, $[**]; and general aggregate (commercial form only), $[**].

 

(b)            The
foregoing policies will provide primary coverage to COH and shall name the COH Indemnitees as additional insureds, and shall remain in
effect during the term of this Agreement and for [**] following the termination or expiration of the term of this Agreement. The COH Indemnitees
shall be notified in writing by Licensee not less than [**] prior to any material modification, cancellation or non-renewal of such policy.
Licensee’s insurance must include a provision that the coverages will be primary and will not participate with nor will be excess
over any valid and collective insurance or program of self-insurance carried or maintained by the COH Indemnitees. Such insurance coverage
shall be maintained with an insurance company or companies having an A.M. Best’s rating (or its equivalent) of A-XII or better.

 

    23

     

    

 

EXECUTION COPY

 

(c)            Licensee
expressly understands that the coverage limits in Section 10.3(a) do not in any way limit the Licensee’s liability.

 

10.4            LIMITATION
ON DAMAGES. NOTWITHSTANDING ANYTHING CONTAINED IN THIS AGREEMENT TO THE CONTRARY: (I) IN NO EVENT SHALL COH BE LIABLE TO LICENSEE
FOR ANY SPECIAL, PUNITIVE, CONSEQUENTIAL, INDIRECT, OR INCIDENTAL DAMAGES (INCLUDING LOSS OF PROFITS, COSTS OF PROCURING SUBSTITUTE
GOODS, LOST BUSINESS OR ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT) WHETHER BASED UPON BREACH OF WARRANTY, BREACH OF CONTRACT,
NEGLIGENCE, STRICT LIABILITY IN TORT OR ANY OTHER LEGAL THEORY, AND (II) IN NO EVENT SHALL COH BE LIABLE TO LICENSEE FOR AN AGGREGATE
AMOUNT IN EXCESS OF ONE-HALF OF THE TOTAL CONSIDERATION PAID TO COH HEREUNDER.

 

ARTICLE 11: CONFIDENTIALITY

 

11.1            Confidential
Information. During the term of this Agreement and for [**] thereafter without regard to the means of termination: (i) COH
shall not use, for any purpose other than the purpose contemplated by this Agreement, or reveal or disclose to any Third Party any Licensee
Confidential Information; and (ii) Licensee shall not use, for any purpose other than the purpose contemplated by this Agreement,
or reveal or disclose any COH Confidential Information to any Third Party. The Parties shall take reasonable measures to assure that no
unauthorized use or disclosure is made by others to whom access to such other Party’s Confidential Information is granted.

 

11.2            Exceptions.
Notwithstanding the foregoing, a Party may use and disclose Confidential Information of the other Party as follows:

 

(a)            if
required by applicable law, rule, regulation, government requirement and/or court order, provided, that, the disclosing
Party promptly notifies the other Party of its notice of any such requirement and provides the other Party a reasonable opportunity to
seek a protective order or other appropriate remedy and/or to waive compliance with the provisions of this Agreement;

 

(b)            to
the extent such use and disclosure occurs in the filing or publication of any patent application or patent on inventions;

 

(c)            as
necessary or desirable for securing any regulatory approvals, including pricing approvals, for any Licensed Products or Licensed Services,
provided, that, the disclosing Party shall take all reasonable steps to limit disclosure of the Confidential Information
outside such regulatory agency and to otherwise maintain the confidentiality of the Confidential Information;

 

    24

     

    

 

(d)            to
take any lawful action that it deems necessary to protect its interest under, or to enforce compliance with the terms and conditions of,
this Agreement;

 

(e)            to
the extent necessary, to its Affiliates, directors, officers, employees, consultants, vendors and clinicians under written agreements
of confidentiality at least as restrictive as those set forth in this Agreement, who have a need to know such information in connection
with such Party performing its obligations or exercising its rights under this Agreement; and

 

(f)             by
Licensee, to actual and potential investors, licensees, Sublicensees, consultants, vendors and suppliers, and academic and commercial
collaborators, under written agreements of confidentiality at least as restrictive as those set forth in this Agreement.

 

11.3          Certain
Obligations. During the Term and for a period of [**] thereafter and subject to the exceptions set forth in Section 11.2,
Licensee, with respect to COH Confidential Information, and COH, with respect to Licensee Confidential Information, agree:

 

(a)            to
use such Confidential Information only for the purposes contemplated under this Agreement,

 

(b)            to
treat such Confidential Information as it would its own proprietary information which in no event shall be less than a reasonable standard
of care,

 

(c)            to
take reasonable precautions to prevent the disclosure of such Confidential Information to a Third Party without written consent of the
other Party, and

 

(d)            to
only disclose such Confidential Information to those employees, agents and Third Parties who have a need to know such Confidential Information
for the purposes set forth herein and who are subject to obligations of confidentiality no less restrictive than those set forth herein.

 

11.4          Termination.
Upon termination, of this Agreement pursuant to Section 8.2 (but for clarity, not in the case of its Expiration), and upon the request
of the disclosing Party, the receiving Party shall promptly return to the disclosing Party or destroy all copies of Confidential Information
received from such Party, and shall return or destroy, and document the destruction of, all summaries, abstracts, extracts, or other documents
which contain any Confidential Information of the other Party in any form, except that each Party shall be permitted to retain a copy
(or copies, as necessary’) of such Confidential Information for archival purposes or to enforce or verify compliance with this Agreement,
or as required by any applicable law or regulation.

 

ARTICLE 12:
DISPUTE RESOLUTION

 

All Disputes shall be first referred to [**] of
COH (the “COH [**]”) and the [**] of Licensee for resolution, prior to proceeding under the other provisions of this
Article 12. A Dispute shall be referred to such executives upon one Party (the “Initiating Party”) providing the
other Party (the “Responding Party”) with notice that such Dispute exists, together with a written statement describing
the Dispute with reasonable specificity and proposing a resolution to such Dispute that the Initialing Party is willing to accept, if
any. Within [**] after having received such statement and proposed resolution, if any, the Responding Party shall respond with a written
statement that provides additional information, if any, regarding such Dispute, and proposes a resolution to such Dispute that the Responding
Party is willing to accept, if any. In the event that such Dispute is not resolved within [**] after the Responding Party’s receipt
of the Initiating Party’s notice, either Party may bring and thereafter maintain suit against the other with respect to such Dispute;
provided, however, that the exclusive jurisdiction of any such suit shall be the state and federal courts located in Los Angeles County,
California, and the Parties hereby consent to the exclusive jurisdiction and venue of such courts.

 

    25

     

    

 

EXECUTION COPY

 

ARTICLE 13: GOVERNMENTAL MATTERS

 

13.1          Governmental
Approval or Registration. If this Agreement or any associated transaction is required by the law of any nation to be either approved
or registered with any governmental agency, Licensee shall assume all legal obligations to do so. Licensee shall notify COH if it becomes
aware that this Agreement is subject to a U.S. or foreign government reporting or approval requirement. Licensee shall make all necessary
filings and pay all costs including fees, penalties and all other out-of-pocket costs associated with such reporting or approval process.

 

13.2          Export
Control Laws. Licensee shall observe all applicable U.S. and foreign laws with respect to the transfer of Licensed Products and
related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations and the Export
Administration Regulations.

 

ARTICLE 14: MISCELLANEOUS

 

14.1          Assignment
and Delegation. Except as expressly provided in this Section 14.1, neither this Agreement nor any right or obligation hereunder
shall be assignable in whole or in part, whether by operation of law, or otherwise by Licensee without the prior written consent of COH.
Notwithstanding the foregoing, Licensee or COH, may assign or transfer its rights and obligations under this Agreement to (a) an
Affiliate or (b) a Person that succeeds to all or substantially all of such assignor’s business or assets, whether by sale,
merger, operation of law or otherwise and provided that such Person agrees, in form and substance reasonably acceptable to the non-assigning
Party, to be bound as a direct party to this Agreement in addition to Licensee. This Agreement shall be binding upon and inure to the
benefit of and be enforceable by the Parties hereto and their respective successors and permitted assignees. Any transfer or assignment
of this Agreement in violation of this Section 14.1 shall be null and void.

 

14.2          Entire
Agreement. This Agreement contains the entire agreement between the Parties relating to the subject matter hereof, and all prior
understandings, representations and warranties between the Parties are superseded by this Agreement. For clarity, the Original Agreement
shall be deemed amended and restated in its entirety by and replaced by this Agreement.

 

14.3          Amendments.
Changes and additional provisions to this Agreement shall be binding on the Parties only if agreed upon in writing and signed by the Parties.

 

    26

     

    

 

EXECUTION COPY

 

14.4          Applicable
Law. This Agreement shall be construed and interpreted in accordance with the laws of the State of California and all rights and
remedies shall be governed by such laws without regard to principles of conflicts of law.

 

14.5          Force
Majeure. If the performance of this Agreement or any obligations hereunder is prevented, restricted or interfered with by reason
of earthquake, fire, flood or other casualty or due to strikes, riot, storms, explosions, acts of God, war, terrorism, or a similar occurrence
or condition beyond the reasonable control of the Parties, the Party so affected shall, upon giving prompt notice to the other Parties,
be excused from such performance during such prevention, restriction or interference, and any failure or delay resulting therefrom shall
not be considered a breach of this Agreement.

 

14.6          Severability.
The Parties do not intend to violate any public policy or statutory common law. However, if any sentence, paragraph, clause or combination
of this Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph, clause or combination
of the same shall be deleted and the remainder of this Agreement shall remain binding, provided that such deletion does not alter
the basic purpose and structure of this Agreement.

 

14.7          Notices.
All notices, requests, demands, and other communications relating to this Agreement shall be in writing in the English language and shall
be delivered in person or by mail, international courier or facsimile transmission (with a confirmation copy forwarded by courier or mail).
Notices sent by mail shall be sent by first class mail or the equivalent, registered or certified, postage prepaid, and shall be deemed
to have been given on the date actually received. Notices sent by international courier shall be sent using a service which provides traceability
of packages. Notices shall be sent as follows:

 

	Notices to COH:	with a copy to:
	 	 
	
    Office of Technology Licensing

    City of Hope

    1500 East Duarte Road

    Duarte, CA 91010

    Attn: VP, Center for Applied Technology Development

    Fax [**]
	
    Office of General Counsel

    City of Hope

    1500 East Duarte Road

    Duarte, CA 91010

    Attn: General Counsel

    Fax [**]

	 	 
	Notices to Licensee:	with a copy to:
	 	 
	
    Akriveia Therapeutics Inc.

    23 Southern Hills Drive,

    Skillman, New Jersey 08558
	
    Morrison & Foerster LLP

    12531 High Bluff Drive, Suite 100

 San Diego, CA 92130

 

Either Party may change its address, or the addition
or deletion of “copied” persons or entities for notices or facsimile number at any time by sending notice to the other Party.

 

14.8          Independent
Contractor. Nothing herein shall create any association, partnership, joint venture, fiduciary duty or the relation of principal
and agent between the Parties hereto, it being understood that each Party is acting as an independent contractor, and neither Party shall
have the authority to bind the other or the other’s representatives in any way.

 

    27

     

    

 

EXECUTION COPY

 

14.9          Waiver.
No delay on the part of either Party hereto in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any
single or partial exercise of any power or right hereunder preclude other or further exercise thereof or the exercise of any other power
or right. No waiver of this Agreement or any provision hereof shall be enforceable against any Party hereto unless in writing, signed
by the Party against whom such waiver is claimed, and shall be limited solely to the one event.

 

14.10        Interpretation.
This Agreement has been prepared jointly and no rule of strict construction shall be applied against either Party. In this Agreement,
the singular shall include the plural and vice versa and the word “including” shall be deemed to be followed by the phrase
 “without limitation.” The section headings contained in this Agreement are inserted for convenience only and shall not affect
in any way the meaning or interpretation of this Agreement.

 

14.11        Counterparts.
This Agreement may be executed in counterparts, each of which together shall constitute one and the same Agreement. For purposes of executing
this agreement, a facsimile copy or an emailed PDF of this Agreement, including the signature pages, will be deemed an original.

 

14.12        Licensee
Covenant. Licensee covenants and agrees that, in conducting activities contemplated under this Agreement, it shall comply in all
material respects with all applicable laws and regulations including, without limitation, those related to the manufacture, use, labeling
importation and marketing of Licensed Products and Licensed Services.

 

14.13        Licensee
Certification. Licensee certifies to COH under penalty of perjury, that Licensee has not been convicted of a criminal offense
related to health care, is not currently debarred, excluded or otherwise ineligible for participation in federally funded health care
programs and has not arranged or contracted (by employment or otherwise) with any employee, contractor, or agent that it knew or should
have known are excluded from participation in any federal health care program, and will not knowingly arrange or contract with any such
individuals or entities during the term of this Agreement. Licensee agrees to notify COH in writing immediately of any threatened, proposed
or actual conviction relating to health care, of any threatened, proposed or actual debarment or exclusion from participation in federally
funded programs, of COH or any employee, contractor or agent of COH. Any material breach of this Section 14.13 by Licensee shall
be grounds for termination of this Agreement by COH in accordance with Section 8.2.1.

 

    28

     

    

 

EXECUTION COPY

 

14.14        Publicity.
Neither Party may issue a press releases or otherwise disclose the existence or terms of this Agreement without the prior written consent
of the other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that once the existence
or any terms or conditions of this Agreement has been publicly disclosed in a manner mutually and reasonably agreed-to by the Parties,
either Party may republish the facts previously disclosed without the prior consent of the other Party. COH may, in its sole discretion
and without the approval of Licensee, publicly disclose the existence of this Agreement and the overall potential value of the Agreement
to COH so long as the detailed and specific terms and conditions of this Agreement are not disclosed. If a Third Party inquires whether
a license is available, COH may disclose the existence of the Agreement and the extent of its grant in Section 3.1 to such Third
Party, but will not disclose the name of the Licensee, except where COH is required to release information under either the California
Public Records Act or other applicable law.

 

14.15        No
Third Party Beneficiaries. Except for the rights of the COH Indemnities pursuant to Article 10, nothing in this Agreement,
either express or implied, is intended to or shall confer upon any Third Party any legal or equitable right, benefit or remedy of any
nature whatsoever under or by reason of this Agreement.

 

*        *        *        *        *

 

    29

     

    

 

EXECUTION COPY

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized representatives.

 

	AKRIVEIA THERAPEUTICS INC.	 	CITY OF HOPE
	 	 	 
	By:	/s/ Simon Tomlinson	 	By:	/s/ Robert Stone
	 	 	 	 	 
	Name:	Simon Tomlinson	 	Name:	Robert Stone
	 	 	 	 	 
	Title:	President and CEO	 	Title:	President and CEO

 

    30Exhibit 10.13

 

Certain
identified information has been excluded from the exhibit because it is both (i) not 

material and (ii) is the type of information that
the registrant treats as private or confidential. 

Double asterisks denote omissions.

 

CTLA-4 MONOCLONAL ANTIBODY LICENSE AGREEMENT

 

This LICENSE AGREEMENT (the “Agreement”)
is entered into as of September 26, 2016 between:

 

		A.	WUXI BIOLOGICS (HONG KONG) LIMITED, a Hong Kong corporation having its registration address at Suite 3701-10, 37/F., Jardine
House, 1 Connaught Place, Central, Hong Kong (“WuXi”); and

 

		B.	AKRIVEIA THERAPEUTICS INC., a Delaware corporation having an address at 23 Southern Hills Drive, Skillman, NJ 08558 (“Akriveia”).

 

BACKGROUND:

 

		1.	Akriveia is a company dedicated to the discovery, commercial development and exploitation of proprietary pharmaceutical products
and services.

 

		2.	WuXi is a leading end-to-end biopharmaceutical open-access capability and technology platform with operations in China and
the United States. WuXi has developed mAb molecules that bind a series of therapeutically relevant biological targets.

 

		3.	Akriveia wishes to use its proprietary technology to modify WuXi’s mAb molecules and develop the modified molecules
as therapeutic products. WuXi is willing to license the mAb molecules to Akriveia for this purpose.

 

AGREEMENT:

 

In consideration of the mutual promises and conditions set forth herein
and other good and valuable consideration, WuXi and Akriveia, intending to be legally bound, agree as follows:

 

		1.	Defined Terms

 

		1.1.	The meanings of defined terms used in this Agreement are listed in Appendix 1.

 

		1.2.	Defined terms are capitalized and may (or may not) be in italics.

 

		2.	License

 

		2.1.	Exclusive License Grant. WuXi grants to Akriveia - under WuXi’s rights in the Licensed Patent
Rights and Licensed Technology - an exclusive, royalty-bearing license to:

 

		2.1.1.	Modify Licensed mAbs using Akriveia Technology (both alone and together with one or more other technologies) for the
purpose of developing Products and for such purpose reproduce and use the Licensed mAbs Materials, and it is understood and agreed
that such modifications by Akriveia using Akriveia Technology, both alone and together with one or more other technologies, are hereby
expressly contemplated, authorized and deemed within scope of the license granted, irrespective
of any rights that may subsequently be granted by WuXi to third parties; and

 

    

     

    

 

		2.1.2.	Manufacture (i.e. make and have made), use, sell, offer for sale and import any Products in the Licensed Territory and
for such purpose reproduce and use the Licensed mAbs Materials and the Licensed Technology.

 

		2.2.	Term of Licenses. The term of the license to Licensed Patent Rights in Section 2.1 will end on expiry of the last of
the Licensed Patent Rights on a country-by-country basis.

 

		2.3.	Paid-Up License. Akriveia will have a paid-up license permitting royalty free manufacture (i.e. making and having made),
use, sale, offer for sale and import of Products in a country after the end of Akriveia’s last obligation to pay royalties
on the Product’s Net Sales in that country.

 

		2.4.	Sub-Licenses.

 

		2.4.1.	Akriveia may sublicense through multiple tiers the licenses in Section 2.1 to: (i) any Affiliate; and (ii) third parties
to permit such Affiliates or third parties:

 

		a.	To make, have made, use, sell, offer for sale or import a Product developed or commercialized by Akriveia or its licensees;
or

 

		b.	To perform services for Akriveia in furtherance of the research, development or commercialization of Products by Akriveia
or its licensees.

 

		2.4.2.	If Akriveia grants a sublicense pursuant to this Section 2.4:

 

		a.	Akriveia will be responsible for the sub-licensee performing in a manner consistent with Akriveia’s obligations
under this Agreement;

 

		b.	Akriveia will not be relieved of its obligations under this Agreement.

 

		2.5.	Retained Rights. Each Party acknowledges that the rights granted under this Section 2 are limited to the scope expressly
granted.

 

		2.5.1.	With the exception of the specific rights granted in this Section 2, WuXi retains all rights in the Licensed Technology
and Licensed Patent Rights including, without limitation,:

 

		a.	The right to develop therapeutic and diagnostic products incorporating the Licensed mAbs but that do not use or incorporate
any Akriveia Technology; and for clarity, no license or other right whatsoever to any Akriveia Technology is granted to
WuXi pursuant to this Agreement;

 

    

     

    

 

		b.	For clarity, Akriveia does not under this Agreement, nor does it have any obligation to grant, to WuXi any rights
in any Patent Rights or other intellectual property rights owned, controlled or licensed by Akriveia that cover any Product.

 

		3.	Technology Transfer.

 

		3.1.	Transfer. In accordance with the Technology Transfer Plan attached as Appendix D WuXi will [**]. Each Party
will [**] in performing the Technology Transfer Plan.

 

		4.	Diligence.

 

		4.1.	Diligence Standards & Decision Making. Akriveia will [**] develop and exploit Products [**]. Akriveia
will have sole authority and discretion to make all decisions relating to [**] in the Licensed Territory .

 

		4.2.	Diligence Reporting

 

		4.2.1.	Annual Development Reports. Akriveia will submit to WuXi a written annual report summarizing the work undertaken
during the year to develop any Products under this License Agreement with the first such annual report due on [**]. Thereafter,
the report must be submitted within [**] after the end of each calendar year.

 

		4.2.2.	Annual Commercialization Report. After a Product is approved for marketing or sale in any country, Akriveia will
submit to WuXi a written annual report summarizing [**] during the previous year and [**] for any Products developed under
this License Agreement. The annual report must be submitted within [**] after the end of each calendar year.

 

		4.3.	Performance of [**]. Akriveia agrees that it will [**] contract with WuXi for WuXi to perform [**] services
[**] for the development of any Products. Notwithstanding the foregoing, Akriveia may [**] if after [**], Akriveia
determines, [**] that:

 

[**].

 

		5.	Payment Terms

 

		5.1.	Upfront Payment. There will be [**] from Akriveia to WuXi under this License Agreement.

 

    

     

    

 

		5.2.	Development Milestones Payments. If a Product achieves a Development Milestone described in Table 1 below, Akriveia
will pay WuXi the sum noted for that milestone. The milestone will not be payable if:

 

		5.2.1.	the Product had previously achieved the milestone and the corresponding milestone payment was paid; or

 

		5.2.2.	the Product is being developed as a back-up to a Lead Product and the Lead Product had previously achieved the
milestone and the corresponding milestone payment was paid; or

 

		5.2.3.	the Product is being developed as a reformulation or other variant form of a Product which had previously achieved the
milestone and the corresponding milestone payment was paid.

 

Each Development Milestone associated payment shall
be payable only once for a given Product (whether a reformulation or variant, or back-up to a Lead Product) such that the
aggregate payable for Development Milestones under this Agreement for each given Product is $[**].

 

Table 1.

 

	Milestone	Payment (USD)
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]

 

		5.3.	Royalty Payments.

 

		5.3.1.	Royalties. Akriveia will pay WuXi a royalty based on a Product’s Net Sales in the Licensed Territory.

 

		5.3.2.	Royalty Rates. The royalty rate will be determined by increments of annual Net Sales of the Product in the Licensed
Territory as set out in Table 2 below, and for clarity, without aggregating the Net Sales of two or more different Products
(such as may be determined or defined by the Regulatory Authority).

 

		5.3.3.	End of Royalties. Akriveia’s obligation to pay royalties will end in each country on the later of:

 

		a.	expiry of the last Valid Claim of a Licensed Patent Right claiming the Product in the country; or

 

    

     

    

 

		b.	[**] from the First Commercial Sale, provided that if at any time after expiry of the Valid Claim as provided in 5.3.3.a,
above, and before the foregoing [**] period is completed, the [**] is reached then Akriveia’s obligation to pay royalties
will immediately end.

 

Table 2.

 

	Annual Net Sales Tiers (USD) for a Product	Royalty
	[**]	[**]
	[**]	[**]
	[**]	[**]

 

		5.4.	Sales Milestone Payments. If a Product achieves a sales performance milestone described in Table 3, Akriveia
will pay WuXi the sum noted for that milestone on a Product-by-Product basis [**]. The milestone payment will only be paid
the first time each Product achieves the sales milestone. The Net Sales used to calculate milestone payments will be based
on Licensed Territory Net Sales of Products on which royalties are payable under Section 5.3.

 

Table 3.

 

	Annual Net Sales (USD) for a Product	Payment (USD)
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]

 

		5.5.	Currency Conversion. The amount of Net Sales in any foreign currency will be computed by:

 

		5.5.1.	Converting the Net Sales into U.S. dollars [**] for the close of the last business day of the calendar quarter for which the
relevant royalty payment is due; and

 

		5.5.2.	Deducting [**].

 

		5.6.	General Payment Matters.

 

		5.6.1.	All payments will be made in U.S. currency by electronic funds transfer.

 

		5.6.2.	All payments [**] will be made within [**] after the payment becomes due.

 

    

     

    

 

		5.6.3.	Royalty payments on Net Sales will be made within [**] after the end of each calendar quarter in which the Net Sales
are made. These payments must be accompanied by a statement showing:

 

		a.	The Net Sales of each Product by Akriveia or any sub-licensee of Akriveia in each country;

 

		b.	The applicable royalty rate(s) for the relevant volume(s) of Net Sales of Product; and

 

		c.	A calculation of the amount of royalty due, including any offsets or credits.

 

		5.7.	Withholding Tax Matters. If any applicable law or regulation of any jurisdiction requires the withholding or payment of any
taxes by Akriveia or any of its Affiliates or sub-licensees pursuant to Section 5, any such taxes [**]. Unless under the
applicable laws or regulations, such payments can [**] Akriveia will [**].

 

 6.

 

		6.1.	Records and Inspection.

 

		6.1.1.	Records. Akriveia [**] of its Net Sales. The records must [**]. The records must be kept for at least [**] from
the date of each royalty or sales milestone payment.

 

		6.1.2.	Inspection. For [**] after a royalty or sales milestone payment, WuXi may [**] appoint an independent, certified public
accountant to inspect the records of Akriveia. The accountant must be reasonably acceptable to Akriveia.

 

		6.1.3.	Notice and Place. Before inspecting the records WuXi must give Akriveia [**] notice. Akriveia must make
the records available for the inspection during regular business hours at the place where the records are usually kept.

 

		6.1.4.	Findings. The accountant’s findings will be binding on the Parties. If the accountant finds that Akriveia
has underpaid, then Akriveia must pay the underpayment to WuXi within [**] of being notified of the finding. If the underpayment
is [**] then Akriveia must reimburse to WuXi the cost of the audit. If the accountant finds that Akriveia has overpaid
WuXi, then the overpayment must be refunded within [**] of WuXi being notified of the finding.

 

		6.1.5.	Timing and Frequency. WuXi may only inspect the records [**] and may only inspect the records for any revenue share
payment [**]. If WuXi does not inspect the records for a royalty or sales milestone payment within [**] of the payment being made, WuXi will be deemed
to have accepted the accuracy of the records.

 

    

     

    

 

		6.1.6.	Confidentiality. All information about Akriveia’s financial affairs learned by a WuXi during an inspection
will be deemed Akriveia’s Confidential Information. It is understood and agreed that the accountant will disclose
to WuXi only that information necessary to report the accuracy and completeness of Akriveia’s royalty and sales milestone
payments to WuXi.

 

		7.	Confidentiality

 

		7.1.	Non-Disclosure. Except as provided in this Section 7 below, a Receiving Party may not disclose to a third party the
following information without the written permission of the Disclosing Party:

 

		7.1.1.	Disclosing Party’s Confidential Information disclosed under this Agreement.

 

		7.1.2.	Any information deemed to be the Confidential Information of both Parties.

 

		7.1.3.	The terms of this Agreement.

 

		7.2.	Permitted Disclosures

 

		7.2.1.	Required by Law. If a Receiving Party is required by law to disclose the information listed in Section 7.1, it must
give the Disclosing Party prompt notice and cooperate with Disclosing Party if it seeks - at its expense - a protective
order. If the Disclosing Party faits to obtain a protective order, the Receiving Party may - without the other’s permission
- disclose the information that its legal counsel advises it is required to disclose.

 

		7.2.2.	Staff. The Parties may disclose the information listed in Section 7.1 to their officers, employees, agents and consultants
(“Staff”). . The Staff must be bound by contract to maintain such information in confidence on the same terms as are set forth
in this Section 7

 

		7.2.3.	Sub-Licensees & other Third Parties. Akriveia may disclose the information in Section 7.1.1 to a third party: (i)
for use under a sublicense that Akriveia is entitled to grant under this Agreement; or (ii) providing services to Akriveia
with respect any Product. The third party must be bound by contract to maintain such information in confidence on the same terms
as are set forth in this Section 7.

 

		7.2.4.	Potential Investors. A Party may disclose the terms of this Agreement to its:

 

		a.	advisors;

 

    

     

    

 

		b.	any potential investor that would qualify as accredited as defined in 17 C.F.R. Section 230.501

 

		c.	investment bankers; and

 

		d.	any potential acquirer of substantially all of the assets to which this Agreement relates or any potential sublicensee or potential
commercialization partner.

 

		7.3.	Use. The Parties may only use the information listed in Section 7 as expressly permitted by this Agreement. Akriveia
may only use WuXi’s Confidential Information within the scope of the licenses granted hereunder including under Section
2.

 

		7.4.	Measures.

 

		7.4.1.	General Measures. The Parties will use the same measures to protect the other’s Confidential Information
as it uses to protect its own Confidential Information. Each Party must ensure that each of its officers, employees, agents
and consultants that will have access to the other’s Confidential Information are bound by contract to maintain the information
in confidence. Further a Party must ensure that each of the individuals or entities listed in Section 7.2.4 are bound by contract
to maintain the terms of this Agreement in confidence.

 

		7.4.2.	Special Measures. During performance of any Technology Trannsfer Plan under Section 3, Akriveia must, prior to
disclosing the sequence or structural information of any Licensed mAb to any person, notify WuXi in writing of the person
or persons that it intends disclosing such information to, provide WuXi with a copy of the relevant confidentiality agreement between
Akriveia and such persons and obtain WuXi’s written consent, provided that the foregoing procedure will not be required
with respect to Akriveia’s designated laboratory.

 

		7.5.	Return of Information. After termination of this Agreement, a Receiving Party will, on the Disclosing Party’s
request, return or destroy all copies of documents provided by Disclosing Party that contain the requesting Disclosing Party’s
Confidential Information. But, one (1) copy may be kept so that the Receiving Party can monitor its continuing obligations
under this Section 7. The Confidential Information will be returned within [**] of the request.

 

		7.6.	Duration. The obligations of this Section 7 will end if the information listed in Section 7 enters the public domain through
no fault of the Receiving Party that received the information.

 

    

     

    

 

 

		8.	Restrictions on Materials.

 

		8.1.	Permitted Transfer. Akriveia may transfer Licensed mAb Materials to a third party:

 

		8.1.1.	for use under a sublicense that Akriveia is entitled to grant under this Agreement; or

 

		8.1.2.	engaged by Akriveia to perform services with respect to any Product.

 

		8.2.	Permitted Use. Akriveia may only use the Licensed mAb Materials as contemplated by this Agreement including as
contemplated by Section 2.1.2.

 

		8.3.	Restricted Use & Transfer. Other than as provided in Section 8.1 and 8.2, Akriveia may not transfer Licensed
mAb Materials to a third party or use the Licensed mAb Materials without the written permission of WuXi.

 

		9.	Bankruptcy.

 

		9.1.	Intellectual Property. All rights granted under this Agreement by WuXi are, for the purposes of Article 36S(n) of the
U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Article 101 of the U.S. Bankruptcy Code.
The Parties agree that:

 

		9.1.1.	Rights and Elections. Akriveia will retain - and may fully exercise - all of its rights and elections under the U.S.
Bankruptcy Code, or equivalent legislation in any other jurisdiction.

 

		9.1.2.	Delivery of Intellectual Property. In the event a bankruptcy proceeding is commenced by or against WuXi under the U.S.
Bankruptcy Code, Akriveia will be entitled to a complete duplicate of (or complete access to, as appropriate) the intellectual
property and its embodiments. If the intellectual property and its embodiments are not already in Akriveia’s possession,
they must be promptly delivered to Akriveia at Akriveia’s request when:

 

		a.	The bankruptcy proceeding is commenced, unless WuXi elects to continue to perform all of its obligations under this Agreement;
or

 

		b.	This Agreement is rejected by or on behalf of WuXi.

 

		10.	Patent Filing, Prosecution & Maintenance

 

		10.1.	WuXi’s Obligations. WuXi will [**] file, prosecute, maintain and enforce Licensed Patent Rights, provided,
however, WuXi will: (a) [**] grant to Akriveia rights to enforce the Licensed Patent Rights [**] if the rights to
develop and commercialize the Licensed mAb as an unmodified antibody have not been granted by WuXi to a third party licensee
within [**] after the Effective Date, and upon Akriveia request from time-to-time, WuXi
will provide updates on status of such out-license effort; and (b) until rights to enforce have been granted to Akriveia, upon
Akriveia’s notice of infringing activity in the Field, WuXi will consider in good faith enforcing the Licensed
Patents Rights against the infringers with the assistance of, and at the sole cost and expense of Akriveia.

 

     

     

    

 

		10.2.	Defense. If a third party brings suit against Akriveia or any sub-licensee alleging that Akriveia’s practice
of Licensed Patent Rights [**] infringes the third party’s intellectual property rights:

 

		10.2.1.	Akriveia must give WuXi [**] written notice and give WuXi a copy of each communication relating to the alleged
infringement;

 

		10.2.2.	WuXi must[**] cooperate with Akriveia’s defense of the suit;

 

		10.2.3.	WuXi will authorize Akriveia to conduct and dispose of the suit;

 

		10.2.4.	Akriveia must obtain WuXi’s consent to any part of settlement that contemplates payment or other action by WuXi
or waiver, amendment or abandonment of any Licensed Patent Rights [**];

 

		10.2.5.	Akriveia may, at its expense, require WuXi to institute or join any defense and WuXi must execute all documents
and take all other actions, which may reasonably be required in connection with the defense.

 

		11.	Term and Termination

 

		11.1.	Term. Unless sooner terminated, this Agreement will end on the last obligation of Akriveia to pay royalties under
this License Agreement.

 

		11.2.	Breach Events. The following will be breach events (“Breach Events”):

 

		11.2.1.	Any representation or warranty of a party under this Agreement proves to have been incorrect in any material respect when made.

 

		11.2.2.	A party fails in any material respect to perform or observe any term of this Agreement. But, only if the failure remains un-remedied
for [**] after written notice from the other Party.

 

		11.3.	Termination.

 

		11.3.1.	A Party may terminate this Agreement [**] if the other Party is responsible for a Breach Event by giving written
notice, provided that if the alleged breaching Party disputes the existence or materiality of a Breach Event in a notice
provided to the non-breaching Party, then the non-breaching Party shall have no right to terminate this Agreement unless and until
the arbitrator (per Section 16.2) has confirmed such existence and materiality, and thereafter, the breaching Party has failed
to cure such breach within [**] after the arbitrator’s decision.
It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in
effect and the Parties shall continue to perform all of their respective obligations hereunder. The Parties agree that [**] for any Product
[**], termination pursuant to this Section 11.3 is a remedy to be invoked only if the breach cannot be adequately remedied through specific
performance and/or payment of money damages.

 

     

     

    

 

		11.3.2.	Akriveia may terminate this Agreement at anytime without cause by giving WuXi 90 days written notice.

 

		11.4.	Effect of Termination.

 

		11.4.1.	Termination of this Agreement will not prejudice:

 

		a.	The following terms which will survive termination, Sections 5.5, 6, 7, 8, 11.2, 12, 13, 14;

 

		b.	A party’s right to receive any payments accrued under and in accordance with Section 5; or

 

		c.	Any other remedies which either party may otherwise have.

 

		11.4.2.	On the date of termination:

 

		a.	Licenses. The license under Section 2 will immediately terminate.

 

		b.	Use of Licensed mAb. Akriveia must; (i) immediately and forever cease research, development or commercialization of
any Product; and (ii) must at WuXi’s request destroy all Licensed mAb Materials in its or its sub-licensee’s
possession.

 

		12.	Representations & Warranties

 

		12.1.	General. WuXi and Akriveia each represents and warrants to the other as follows:

 

		12.1.1.	It is a corporation duly organized, validly existing and is in good standing under the laws of Hong Kong in the case of WuXi
and Delaware in the case of Akriveia.

 

		12.1.2.	It is qualified to do business and is in good standing in each jurisdiction in which it conducts business.

 

		12.1.3.	It has all the power and authority to conduct its business as now being conducted.

 

     

     

    

 

		12.1.4.	It has all power and authority to enter into and perform this Agreement.

 

		12.1.5.	This Agreement has been duly authorized by all necessary corporate action and will not:

 

		a.	require the consent of its stockholders;

 

		b.	violate any applicable law;

 

		c.	violate its certificate of incorporation or by-laws; or

 

		d.	breach any material agreement, permit or other instrument that binds it or its assets.

 

		12.1.6.	It does not owe an obligation to a third party that conflicts with this Agreement or that would impede its performance of this
Agreement.

 

		12.1.7.	It has sufficient rights in its tangible and intangible assets to perform this Agreement and it is not aware that a third party
disputes these rights.

 

		12.2.	IP Representation & Warranty. WuXi hereby represents and warrants that:

 

		12.2.1.	WuXi has no knowledge of any information that adversely affects the validity or enforceability of the Licensed Patent Rights
or WuXi’s rights in the Licensed Technology;

 

		12.2.2.	The Licensed Patent Rights or Licensed Technology are not subject to any claim of invalidity, misuse, unenforceability
or non-infringement;

 

		12.2.3.	WuXi is the sole legal and beneficial owner of the Licensed Patent Rights and Licensed Technology and no license
or other right in any of the foregoing that would conflict or restrict the rights granted to Akriveia under Section 2 of this Agreement
has been or will be granted to any third party.

 

		12.3.	IP Licensees Coexistence Covenant. WuXi hereby covenants with Akriveia that:

 

		12.3.1.	WuXi will not grant a license or other right to a third party in the Licensed Patent Rights and Licensed Technology
that would conflict with or restrict the rights granted to Akriveia under Section 2 of this Agreement;

 

		12.3.2.	WuXi will include in any agreement granting a third party licenses or rights to the Licensed Patent Rights or Licensed
Technology a contractual provision substantially equivalent in meaning to the following:

 

‘‘This license
expressly excludes any rights whatsoever to research, develop or commercialize any pharmaceutical products developed through [**] of
the Licensed mAb with the purpose of [**] through selective activation of [**].

 

Licensee acknowledges that WuXi
has granted to a third party exclusive rights under the Licensed Patent Rights and Licensed Technology to [**] pharmaceutical
products by modifying the Licensed mAb through [**] of the Licensed mAb with the purpose of [**] through selective activation
of [**], both by itself and together with one or more other technologies, with no restrictions as to the nature or type of technologies.
Accordingly, the exclusivity of any license granted to licensee may be limited by the rights already granted by WuXi to the aforementioned
third-party. Licensee further acknowledges that the pharmacologically active molecule of the third-party’s products, after selective
activation, may be similar or identical to a Licensed mAb”

 

     

     

    

 

		12.3.3.	Within [**] of entering into an agreement granting a third party any rights in the Licensed Patent Rights or Licensed Technology,
WuXi will notify Akriveia in writing. The notice will identify the third party, the Licensed mAb and the territory
of the rights granted. The notice will also include a certification from WuXi of compliance with the covenants in 12.3.1 and 12.3.2 above.

 

		13.	Covenants.

 

		13.1.	During the Agreement, WuXi and Akriveia each covenant to the other that it will:

 

		13.1.1.	Preserve its corporate existence.

 

		13.1.2.	Remain qualified to do business in good standing in each jurisdiction in which it conducts business.

 

		13.1.3.	Maintain the rights in its tangible and intangible assets needed to perform this Agreement.

 

		13.1.4.	Not accept an obligation to a third party that conflicts with this Agreement or that would impede its performance of this Agreement.

 

		13.1.5.	Comply in all material respects with the requirements of all applicable laws.

 

		13.2.	Akriveia covenants that it will not:

 

		13.2.1.	[**] Products in [**].

 

     

     

    

 

		13.2.2.	Manufacture, use, sell, offer for sale or import the Licensed mAbs or any derivatives or modifications of Licensed mAbs
except as expressly permitted under this Agreement (namely, as one or more Products).

 

		14.	Indemnities.

 

		14.1.	Akriveia Indemnity. Akriveia will indemnify WuXi and its Affiliates, and its or their officers, directors,
shareholders, employees, agents and representatives (“WuXi Indemnified Parties”) against all liability and costs
resulting from any third party claim made against an WuXi Indemnified Party arising from:

 

		a.	Akriveia’s breach of any of its representations, warranties or covenants in Sections 12 and 13; or

 

		b.	Akriveia’s manufacture, sale, offer for sale, use or import of a Product.

 

		14.1.1.	Control. On receipt of notice of the claim, WuXi Indemnified Party must:

 

		a.	Promptly notify Akriveia.

 

		b.	Permit Akriveia [**] to handle and control the defense and settlement of the claim. But, WuXi Indemnified Party will
have the right to participate in the defense of the claim at its own expense.

 

		c.	Give Akriveia [**] all reasonable assistance in Akriveia’s handling of the claim.

 

		14.1.2.	Exclusions. This indemnity will not apply to the extent any claim arises out of a WuXi Indemnified Party’s negligence,
willful misconduct or breach of any term, representation, warranty or covenant in this Agreement.

 

		14.2.	WuXi Indemnity. WuXi will indemnify Akriveia and its Affiliates, and its or their officers, directors,
shareholders, employees, agents and representatives (“Akriveia Indemnified Parties”) against all liability and
costs resulting from any third party claim made against an Akriveia Indemnified Party arising from WuXi’s breach of
any of its representations, warranties or covenants in Sections 12 and 13.

 

		14.2.1.	Control. On receipt of notice of the claim, Akriveia Indemnified Party must:

 

		a.	Promptly notify WuXi.

 

		b.	Permit WuXi [**] to handle and control the defense and settlement of the claim. But, Akriveia Indemnified Party will
have the right to participate in the defense of the claim at its own expense.

 

		c.	Give WuXi [**] all reasonable assistance WuXi’s handling of the claim.

 

     

     

    

 

		14.2.2.	Exclusions. This indemnity will not apply to the extent any claim arises out of an Akriveia Indemnified Party’s
negligence, willful misconduct or breach of any term, representation, warranty or covenant in this Agreement.

 

		15.	Notices.

 

		15.1.	All notices will be in writing and sent by certified mail, return receipt requested, courier, or facsimile to the addresses noted
below. Notices will be deemed given on the date it is received.

 

		15.1.1.	If to Akriveia:	23 Southern Hills Drive, Skillman, NJ 08558, USA

Attention: CEO

 

		15.1.2.	If to WuXi:	WuXi AppTec, Building 1, 288 Fute Zhong Road,

Waigaoqiao Free Trade Zone, Shanghai, China 200131

Attention: CEO

 

		16.	Miscellaneous

 

		16.1.	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, U.S.A.,
but without applying its conflicts of laws rules.

 

		16.2.	Dispute Resolution. If a dispute cannot be resolved within [**] it will be finally settled by binding arbitration in San Francisco
conducted according to the then current Rules of Arbitration of the International Chamber of Commerce and in the English language. Each
Party has the right to institute an action in a court of proper jurisdiction for injunctive or other equitable relief pending a
final decision by the arbitrator.

 

		16.3.	Binding Effect. This Agreement is binding upon and inures to the benefit of a Party’s legal representatives,
successors and permitted assigns.

 

		16.4.	Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an original.

 

		16.5.	Amendment. This Agreement may only be amended or canceled in writing.

 

		16.6.	Waiver. A Party’s compliance with the terms of this Agreement may only be waived by written notice from
the other Party. Unless stated otherwise a waiver will not be deemed an ongoing waiver. Any delay or failure of a Party
to require performance of a term of this Agreement will not prevent the Party from enforcing the term later.

 

     

     

    

 

		16.7.	Third Party Beneficiaries. No third party has any rights under this Agreement.

 

		16.8.	Relationship. The Parties are independent contractors. This Agreement does not create a partnership between the
Parties or any third party.

 

		16.9.	Assignment and Successors. A Party may not assign this Agreement without the permission of the other Party.
But, a Party may - without the permission of the other Party - assign this Agreement to:

 

		16.9.1.	Its Affiliates;

 

		16.9.2.	Any purchaser of all or substantially all of its assets to which this Agreement relates; or

 

		16.9.3.	Any successor corporation resulting from any merger or consolidation of such Party with or into such corporations;

 

		16.10.	Force Majeure. A Party will not be in breach or liable for any failure or delay of its performance of this Agreement
caused by natural disasters or circumstances reasonably beyond its control.

 

		16.11.	Severability. If any provision of this Agreement is invalid or is unenforceable, the Parties intend that the
remainder of the Agreement will be unaffected.

 

		16.12.	Other Agreements. This Agreement is the sole agreements between the Parties with respect to the Licensed Technology.

 

		16.13.	Conflicts. In case of any conflicts in the terms and conditions of this Agreement and the terms and conditions of any
Appendices to this Agreement, the terms and conditions of this Agreement shall govern.

 

[Signature page follows]

 

     

     

    

 

This Agreement was executed on the date stated in the introductory
clause.

 

	WUXI BIOLOGICS (HONG KONG) LIMITED		AKRIVEIA
                                            THERAPEUTICS INC.

 

	By:	/s/ Jing Li		By:	/s/ Simon Tomlinson

 

	Name:	Jing Li		Name:	Simon Tomlinson  

 

	Title:	Vice President		Title:  	Chief Executive Officer 

	Date:	Sept. 26, 2016		Date:	Sept.
28, 2016  

 

     

     

    

 

 

Index of Appendices

 

1.       Appendix A – Definitions

 

2.       Appendix B – Licensed
mAb Materials

 

3.       Appendix C – Licensed
Patent Rights

 

4.       Appendix D – Technology
Transfer Plan

 

     

     

    

 

Appendix A

 

Definitions

 

	“Affiliate”	
    Means with respect to any Party, any person or entity controlling,
    controlled by or under common control with such Party.

     

    For purposes of this definition, “control” means:

     

    a)       Direct
    or indirect ownership of fifty percent (50%) or more of the stock or shares having the right to vote for the election of directors of
    such corporate entity; or

     

    b)       the
    possession directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such entity, whether
    through the ownership of voting securities, by contract or otherwise.

     

	“Akriveia Technology”	Means any approach to [**] of an antibody with the purpose of [**] through selective activation of [**].
	“[**]”	Means [**].
	“China Territory”	Means
    the People’s Republic of China including Hong Kong and Macau.
	“Commencement of Phase I”	Means [**] in a Phase I clinical trial initiated by or on behalf of Akriveia anywhere in the Licensed Territory.
	“Commencement of Phase II”	Means [**] in a Phase II clinical trial initiated by or on behalf of Akriveio anywhere in the Licensed Territory.
	“Commencement of Phase III”	Means [**] in a Phase III clinical trial initiated by or on behalf of Akriveia anywhere in the Licensed Territory.
	“Commercially Reasonable Efforts”	Means those efforts and resources that Akriveia would use were it developing or commercializing its own pharmaceutical products that are of similar market potential as the Product, taking into account [**], all as measured by the facts and circumstances at the time such efforts are due.

 

     

     

    

 

	“Confidential Information”	
    Means all information disclosed by one Party to the other and
    which is designated as confidential in writing at the time of disclosure or if disclosed orally, summarized or referenced in a writing
    within [**] after the oral disclosure by:

     

    (a)      the
    Disclosing Party;

     

    (b)      a
    third party acting on the Disclosing Party’s behalf; or

     

    (c)      a
    third party under an obligation of confidence to the Disclosing Party.

     

    All WuXi Licensed Technology other than Licensed Patent Rights
    that have been published will be deemed WuXi’s Confidential Information.

     

    All Information pertaining to Akriveia Technology or the development
    and/or commercialization of Products hereunder (including the contents of all Development and Commercialization reports provided to WuXi)
    will be deemed Akriveia’s Confidential Information.

     

    The following information is not included in this definition. Information,
    as established by contemporaneous business records kept in the ordinary course, that:

     

    a.       at
    the time of receiving the information such information was already known by the Receiving Party without any restriction on disclosure
    with respect to such information;

     

    b.       is
    furnished to the Receiving Party by a third party without restriction on disclosure; or

     

    c.       is
    independently developed by the Receiving Party without reference to any of the Disclosing Party’s Confidential Information.

     

	“Control”, “Controlled” or 

 “Controller”	Means with respect to any intellectual property right, the possession (whether by ownership or license, other than a license granted by one Party to the other pursuant to this Agreement) by a Party of the ability to grant to the other Party a license or to extend other rights as provided herein, under such first Party’s intellectual property right without violating the terms of any agreement or other arrangements with any third party.
	“Disclosing Party”	Means a Party that discloses or is deemed to disclose its own Confidential Information to the other Party. With respect to any Confidential Information that is deemed to be the Confidential Information of both Parties then with respect to a Party in possession of such information the other Party will be considered the Disclosing Party.
	“Effective Date”	Means the date set forth at the top of the first page of this Agreement.
	“Field”	Means prevention and treatment of [**].
	“Indemnified Parties”	Is defined in Section 13.1 and 13.2.
	“Lead Product”	Is a Product for which Akriveia is developing an alternative Product that binds the same biological target and is being developed for the same therapeutic indications as a backup in case the initial Product’s development is terminated or delayed.

 

     

     

    

 

	“Licensed mAbs”	Means the monoclonal antibody molecules described in Appendix B.
	“Licensed mAb Materials”	Means any tangible samples of Licensed mAbs [**]: (i) provided by WuXi to Akriveia; or (ii) propagated or duplicated by Akriveia in the course of conducting the development and commercialization activities under this Agreement, in each case as listed in Appendix B.
	“Licensed Patent Rights”	Means (i) all the Patent Rights listed in Exhibit F to this Agreement, and (ii) all other Patent Rights owned, in-licensed or otherwise controlled by WuXi or its Affiliates during the term of the Agreement with the right to sublicense (where applicable), that cover the Licensed mAbs or any of the Products.
	“Licensed Technology”	Means the Licensed mAbs, Licensed mAb Materials, Licensed Patent Rights and all associated data, information and know-how.
	“Licensed Territory”	Means [**]
	“Net Sales”	
    means the gross sales of a Product by Akriveia, its Affiliates,
    or its sub-licensees to third parties, less the following deductions:

     

    [**]

      

 

     

     

    

 

	“Party” or “Parties”	WuXi and Akriveia are referred to in this Agreement collectively as the “Parties” and individually as a “Party”
	“Patent Rights”	Means all the Valid Claims of patent applications and issued patents, whether domestic or foreign, including all continuations, continuations-in-part, divisions, and renewals, and letters of patent granted thereon, and all reissues, re-examination and extensions thereof and any patent restoration or extension period granted by a governmental authority, including but not limited to compensation for patent term lost during the clinical trial or regulatory approval process.
	“Product”	Means any product in the Field that is developed by or on behalf of Akriveia or any of its sub-licensees that incorporates a Licensed mAb that has been modified using Akriveia’s Technology either alone or together with one or more other technologies.
	“Receiving Party”	Means a Party that receives or is deemed to receive from the other Party the Confidential Information of such other Party.  With respect to any Confidential Information that is deemed to be the Confidential Information of both Parties then with respect to a Party in possession of such information it will be considered the Receiving Party.
	“Regulatory Approval”	Means, with respect to a nation or, where applicable, a multinational jurisdiction, any approvals, licenses, registrations or authorizations granted by Regulatory Authority necessary for the manufacture, marketing and sale of a Product in such nation or such jurisdiction.
	“Regulatory Authority”	Means any national (e.g., FDA), supranational (e.g., the EMEA), regional, state or local regulatory agency that has authority to grant Regulatory Approval of pharmaceutical products.
	“Valid Claim”	Means a claim within Patent Rights so long as such claim shall not have been disclaimed by WuXi or shall not have been held invalid in a final decision rendered by a tribunal of competent jurisdiction from which no appeal has been or can be taken.

 

     

     

    

 

CONFIDENTIAL

Execution Copy  

 

AMENDMENT

TO THE

CTLA-4 MONOCLONAL ANTIBODY LICENSE AGREEMENT

BY AND BETWEEN

WUXI BIOLOGICS (HONG KONG) LIMITED AND AKRIVEIA CONCERTO LLC.

 

This AMENDMENT (the “Amendment”) amends the CTLA-4
Monoclonal Antibody License Agreement, dated September 26, 2016 (“Agreement”) entered into by and between WuXi Biologics (Hong
Kong) Limited, a Hong Kong corporation having its registered address at Suite 3701-10 , 37/F, Jardine House, 1 Connaught Place, Central,
Hong Kong (“WuXi”) and Akriveia Concerto LLC, a Delaware corporation having an address at 23 Southern Hills Drive,
Skillman, NJ 08558 (as successor in interest to Akriveia Therapeutics Inc.) (“Akriveia”), and is effective as of December
30th, 2017 (“Amendment Effective Date”). Capitalized terms in this Amendment will have the meanings set forth in the
Agreement.

 

		A.	Pursuant to the Agreement, WuXi granted to Akriveia a license under the Licensed Patent Rights to use its proprietary technology to
develop and modify WuXi’s mAb molecules and develop and commercialize such molecules as therapeutic products.

 

		B.	The Parties wish to amend the Agreement to expand the scope of the existing exclusive license under the Licensed Patent Rights in
accordance with the terms and conditions of this Amendment.

 

Notwithstanding anything to the contrary contained in the Agreement,
and in consideration of the mutual promises and covenants set forth in the Agreement and this Amendment, the receipt and sufficiency of
which are hereby acknowledged, and pursuant to Section 16.5 of the Agreement, the Parties agree as follows:

 

		1.	The Parties agree to amend Appendix A of the Agreement to replace the definitions of “Licensed mAbs”, “Licensed
mAbs Materials”, “Licensed Patent Rights”, “Licensed Territory” and “Product”
in their entirety with the following:

 

“Licensed mAbs” means (i) any and all antibodies
disclosed in the Licensed Patent Rights, together with (ii) [**], and (iii) [**] of (i) or (ii).

 

“Licensed mAbs Materials” means any tangible
samples of Licensed mAbs and their associated cell-lines and nucleic acid vectors: (i) provided by WuXi to Akriveia, or (ii) propagated
or duplicated by Akriveia in the course of conducting the development and commercialization activities under this Agreement.

 

“Licensed Patent Rights” means (i) all the
Patent Rights listed in Appendix C to this Agreement, and (ii) all other Patent Rights owned, in-licensed or otherwise controlled
by WuXi or its Affiliates during the term of the Agreement with the right to sublicense (where applicable), that cover the licensed mAbs
or any of the Products.

 

    1

     

    

 

CONFIDENTIAL

Execution Copy  

 

“Licensed Territory” means any country in
the world including the China Territory.

 

“Product” means any product in the Field
that is developed by or on behalf of Akriveia or any of its sub- licensees that incorporates a Licensed mAb.

 

2.       The Parties agree to amend
Appendix A of the Agreement to add the following:

 

“Fab” means a fragment of an antibody that contains
[**].

 

“First Commercial Sale” means the first sale of
any Product under this Agreement following Regulatory Approval of such Product anywhere in the Licensed Territory.

 

		3.	The Parties agree to amend Section 2 of the Agreement to replace that section in its entirety with the following:

 

2.            License

 

		2.1	Exclusive License Grant. WuXi grants to Akriveia, under WuXi’s rights in the Licensed Patent Rights and Licensed Technology,
an exclusive (even as to WuXi), sublicensable (subject to Section 2.4), transferable (subject to Section 16.9), royalty-bearing license
to make, have made, use, sell, offer for sale, import and export any Products and for such purpose reproduce and use the Licensed Technology
(and the Licensed mAbs Materials contained therein) in the Licensed Territory.

 

		2.2	Term of Licenses. The term of the license to Licensed Patent Rights in Section 2.1 will end on expiry of the last of the Licensed
Patent Rights on a country-by-country basis, and thereafter, the license to the Licensed Technology continues on a royalty-free basis
in perpetuity.

 

		2.3	Paid-Up License. Akriveia will have a paid-up license permitting royalty-free manufacture (i.e. making and having made), use, sale,
offer for sale and import of Products in a country after the end of Akriveia’s last obligation to pay royalties on the Product’s
Net Sales in that country and shall have no further obligations to WuXi in that country with respect to such Licensed Patents Rights or
such Products.

 

		2.4	Sub-Licenses. Akriveia may sublicense through multiple tiers the licenses in Section 2.1, on the condition that (a) Akriveia will
be responsible for the sub-licensee performing in a manner consistent with Akriveia’s obligations under this Agreement and (b) Akriveia
will not be relieved of its obligations under this Agreement due to the existence of such sublicense.

 

		2.5	Refrained Rights. Each Party acknowledges that the rights granted under this Section 2 are limited to the scope expressly granted.

 

    2

     

    

 

CONFIDENTIAL

Execution Copy

 

		2.5.1.	With the exception of the specific rights granted in this Section 2, WuXi retains all rights in the Licensed Technology and Licensed
Patent Rights.

 

		2.5.2.	For clarity, (a) Akriveia does not under this Agreement, nor does it have any obligation to, grant to WuXi any rights in any Patent
Rights or other intellectual property rights owned, controlled or licensed by Akriveia that cover any Product; and (b) for clarity, no
license or other right whatsoever to any Akriveia Technology is granted to WuXi pursuant to this Agreement.

 

		2.6.	Grant-Back License. Subject to the terms and conditions of this Agreement, and without limitation of any of Akriveia’s rights
under this Section 2, Akriveia grants to WuXi, under its rights in the licensed Patent Rights and Licensed Technology granted in this
Agreement, a payment-free, royalty-free, non-exclusive, transferable (subject to Section 16.9), license to make, have made, use, sell,
offer for sale, import and export multi-specific antibodies incorporating a Fab from any Licensed mAb in the Licensed Territory together
with at least one Fab derived from an antibody other than a Licensed mAb which additional Fab specifically targets a molecular target
different from the Fob derived from the Licensed mAb. WuXi may sublicense the license granted in this Section 2.6, on the condition that
(a) WuXi will be responsible for the sub-licensee performing in a manner consistent with WuXi’s obligations under this Agreement
(including, without limitation, the preservation of Akriveia’s exclusive rights granted hereunder), and (b) WuXi will not be relieved
of its obligations under this Agreement due to the existence of such sublicense.

 

		4.	As consideration for entry into this Amendment and WuXi’s delivering PCT application to Akriveia, Akriveia will pay WuXi the
sum of [**] dollars (US $[**]) within [**] after the Amendment Effective Date.

 

		5.	The Parties agree to amend Section 5.2 of the Agreement to replace that section in its entirety with the following:

 

		5.2.	Development Milestones Payments. If a Product achieves a Development Milestone described in Table 1 below, Akriveia will pay WuXi
the sum noted for that milestone. The milestone will not be payable if:

 

		5.2.1.	the Product had previously achieved the milestone and the corresponding milestone payment was paid; or

 

		5.2.2.	the Product is being developed as a back-up to a Lead Product and the Lead Product had previously achieved the milestone and the corresponding
milestone payment was paid; or

 

		5.2.3.	the Product is being developed as a reformulation or other variant form of a Product which had previously achieved the milestone and
the corresponding milestone payment was paid.

 

    3 

     

    

 

CONFIDENTIAL

Execution Copy

 

Each Development Milestone associated payment shall be payable
only once for a given Product (whether a reformulation or variant, or back-up to a Lead Product) such that the aggregate payable for Development
Milestones under this Agreement for each given Product is $25,750,000.00; provided, however, that the Regulatory Milestone is payable
more than once by Akriveia if a Regulatory Approval is for a Product that (a) incorporates a different Licensed mAb to an already marketed
Product; and (b) the existing, earlier approved, Product is intended to stay on the market and not be replaced by the subsequently approved
Product (i.e., the later launched Product is not a “backup” that replaces an earlier molecule because it is deemed superior,
but rather will be incorporated in a Product that is marketed alongside an already-launched Product containing a different licensed mAb).

 

Table 1.

 

	Milestone	Payment (USD)
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]

 

As used in this Section 5.2:

 

“[**]” means [**]; and

 

“[**]” means [**].

 

		6.	The Parties agree to amend Sections 5.3.1 and 5.3.2 of the Agreement to replace those sections in their entirety with
the following:

 

		5.3.1	Royalties. Akriveia will pay WuXi a royalty based on the Net Sales of all Products in the Licensed Territory.

 

		5.3.2.	Royalty Rates. The royalty rate will be determined by increments
of annual Net Sales of all Product(s) in the Licensed Territory as set out in Table 2 below. For clarity, the royalty rates set forth
in Table 2 below are payable on the total Net Sales of all Products (i.e., aggregating the Net Soles of all of the Products.

 

		7.	The Parties agree to amend Table 2 in Section 5.3.3 of the Agreement to replace such table in its entirety with the following:

 

    4 

     

    

 

CONFIDENTIAL

Execution Copy

 

Table 2.

 

	
    Annual Net Sales Tiers (USD) for all Products 
	
    Royalty 

	[**]	[**]
	[**]	[**]
	[**]	[**]

 

		8.	The Parties agree to amend Section 5.4 of the Agreement to delete that section in its entirety.

 

		9.	The Parties agree to amend Section 7.4.2 of the Agreement to delete that section in its entirety.

 

		10.	The Parties agree to amend Section 10.1of the Agreement to replace that section in its entirety with the following:

 

	 	10.1.	Patent Prosecution, Maintenance and Enforcement.

 

		10.1	For each patent application and patent under the Licensed Patents Rights, Akriveia shall: (a) prepare, file, and prosecute such patent
application; (b) maintain such patent; (c) [**]; (d) keep WuXi informed of the filing and progress of all material aspects of the prosecution
of such patent application and the issuance of patents from any such patent application; (e) permit WuXi to [**] with respect to the preparation,
filings and prosecution of Licensed Patent Rights; (f) [**] with WuXi concerning any decisions which [**] of such patent application or
patent; and (g) notify WuXi in writing of [**] in the status of such patent or patent application.

 

		10.2	A Party receiving notice of alleged infringement of any of the Licensed Patent Rights in the Licensed Territory shall promptly provide
written notice to the other Party of the alleged infringement. Akriveia shall have first right to bring suit and control the conduct thereof,
including settlement, to stop infringement of any Licensed Patent Rights, as determined by Akriveia. If Akriveia does not commence a particular
infringement action [**], WuXi, after notifying Akriveia in writing, shall be entitled to bring such infringement action at its own expense.
The party conducting such action shall have full control over its conduct. In any event, Akriveia and WuXi shall [**] in any such litigation
[**].

 

		11.	The Parties agree to amend Section 11.4 of the Agreement to replace that section in its entirety with the following:

 

	 	11.4	Effect of Termination

 

	 	11.4.1.	Termination or expiration of this Agreement will not prejudice:

 

		(a)	The following terms, which will survive any termination or expiration: Sections 1, 2.3, 2.5, 2.6, 5.5, 5.6, 5.7, 6.1, 7, 8, 11.4,
13.2, 14, 15, and 16;

 

    5 

     

    

 

CONFIDENTIAL

Execution Copy

 

		(b)	A Party’s right to receive any payment s accrued under and in accordance with Section 5; or

 

		(c)	Any other remedies which either Party might otherwise have.

 

		11.4.2.	On the effective date of termination of this Agreement (other than termination by Akriveia for a Breach Event for which WuXi is responsible):

 

		(a)	Licenses. The license under Section 2 will immediately terminate.

 

		(b)	Use of Licensed mAb. Akriveia must: (i) immediately and forever cease research, development or commercialization of any Product;
and (ii) must at WuXi’ s request destroy all Licensed mAb Materials in its or its sub-licensee’s possession.

 

		11.4.3	On the effective date of termination of this Agreement by Akriveia for a Breach Event for which WuXi is responsible, the license in
Section 2.1 will automatically convert to an exclusive, perpetual, fully paid-up, royalty-free license on the terms set forth in Section
2.3.

 

		12.	The Parties agree to amend Section 12.3 of the Agreement to delete subsections 12.3.2 and 12.3.3 in their entirety.

 

		13.	The Parties agree to amend Section 13.2 of the Agreement to replace that section in its entirety with the following:

 

		13.2	Without limiting Akriveia’s rights under Section 2 of this Agreement, subject to WuXi’s compliance with the terms and
conditions of this Agreement, Akriveia covenants that [**].

 

		14.	The Parties agree to amend Appendix B and D to delete
that Appendix in its entirety.

 

		15.	The Parties agree to amend Appendix C to replace the contents of that Appendix in its entirety with the following:

 

	Title	
    Patent Application No.

     
	
    Jurisdiction

     

	[**]	[**]	[**]

 

 

		16.	To the extent there is any conflict between the terms and conditions of this Amendment and the terms and conditions of the Agreement,
the terms and conditions of this Amendment will control.

 

    6 

     

    

 

CONFIDENTIAL

Execution Copy

 

		17.	Except as set forth in Sections 1 to 16 of this Amendment, all terms and conditions of the Agreement (including the Appendices
to the Agreement) will remain in full force and effect without modification.

 

[SIGNATURES ON NEXT PAGE]

 

    7 

     

    

 

CONFIDENTIAL

Execution Copy

 

IN WITNESS WHEREOF, the Parties to this Amendment
have caused it to be executed by their respective duly authorized representatives as of the Amendment Effective Date.

 

	WuXi Biologics (Hong Kong) Limited	 	Akriveia Concerto LLC
	 	 	 
	By:  	/s/ Chris Chen	 	By:  	/s/ Simon Tomlinson
	 	 	 	 	 
	Name:  	Chris Chen	 	Name:  	Simon Tomlinson
	[Type or Print]	 	[Type or Print]
	 	 	 
	Title:  	CEO	 	Title:  	Chief Executive Officer

 

(Signature Page to Amendment to CTLA-4 Monoclonal
Antibody License Agreement)

 

    8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]